Method for treating or preventing amyotrophic lateral sclerosis

Increasing ASPA activity in ALS patients through gene therapy using rAAV vectors addresses the need for effective ALS treatment by enhancing mitochondrial function and energy metabolism, leading to improved ATP synthesis and motor neuron survival.

JP7587275B2Active Publication Date: 2024-11-20ROWAN UNIVERSITY

Patent Information

Application Number
JP2021511593
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-08-30
Filing Date
2019-08-30
Publication Date
2024-11-20
Estimated Expiration
2039-08-30

AI Technical Summary

Technical Problem

There is a pressing need for effective methods to treat, prevent, or reverse amyotrophic lateral sclerosis (ALS), as current treatments only slow progression and have limited efficacy, and there is no known cure.

Method used

Administering a composition that increases the level or activity of aspartoacylase (ASPA) in cells, particularly through gene therapy using a recombinant adeno-associated virus (rAAV) vector, to enhance mitochondrial oxidative phosphorylation and provide substrates for energy metabolism in ALS patients.

Benefits of technology

The method enhances mitochondrial function, increases ATP synthesis, promotes motor neuron survival, and potentially extends life expectancy in ALS patients by improving energy metabolism and reducing the progression of the disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007587275000003
    Figure 0007587275000003
  • Figure 0007587275000004
    Figure 0007587275000004
  • Figure 0007587275000005
    Figure 0007587275000005
Patent Text Reader

Abstract

The present disclosure provides methods for treating, ameliorating, or reversing at least one symptom of amyotrophic lateral sclerosis (ALS) in a subject by increasing the amount of neuronal aspartate in the spinal cord through administration of a therapeutically effective amount of a composition comprising a nucleic acid encoding ASPA or a functional fragment thereof. [Selection diagram] None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Patent Application No. 62 / 724,780, filed August 30, 2018. The aforementioned application is incorporated herein by reference.

[0002] The present invention relates generally to methods of treating or preventing amyotrophic lateral sclerosis (ALS), and more specifically to methods of treating, alleviating, ameliorating, or reversing ALS in an affected cell population by increasing the intracellular activity of aspartoacylase (ASPA), the rate-limiting component of the malate-aspartate shuttle that provides affected cells with the ability to utilize cytosolic NADH to facilitate mitochondrial oxidative phosphorylation to provide aspartate. [Background technology]

[0003] Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND) or Lou Gehrig's disease, is a disease that causes the death of neurons that control voluntary muscles. It is characterized by adult-onset progressive impairment and loss of upper motor neurons in the motor cortex and lower motor neurons in the brainstem, spinal cord, and their associated cords. Patients with or at risk for ALS present with muscle stiffness, muscle spasms, and progressively worsening weakness due to reduced muscle size. This results in difficulty speaking, swallowing, and eventually breathing.

[0004] There is no known cure for ALS, but the FDA has approved two treatments specifically aimed at slowing the progression of ALS. Riluzole (Rilutek®) was the first FDA-approved drug for ALS and can extend life by approximately 2-3 months in a finite clinical population that presents with bulbar onset. Edaravone (Radicava®) is another FDA-approved treatment option for ALS that is administered intravenously. Clinical data suggests that ALS Functional Rating Scale-R (ALSFRS-R) scores improve compared to the control placebo group. However, the long-term efficacy of edaravone in ALS patients has yet to be determined. Noninvasive ventilation may improve both quality of life and lifespan, but is strictly palliative in nature. The disease can develop in people of any age, but usually begins around age 60 and in hereditary cases around age 50. The average survival time from onset to death is 2-4 years. Approximately 10% survive for more than 10 years, with most dying of respiratory failure.

[0005] Thus, there remains a pressing unmet need in the art to provide methods and reagents for preventing, treating, or reversing ALS. Summary of the Invention

[0006] The present disclosure addresses the above needs in some aspects. In one aspect, the present disclosure provides a method for treating, improving, or reversing at least one symptom of amyotrophic lateral sclerosis (ALS) in a subject in need thereof. The method includes administering to the subject a therapeutically effective amount of a composition that increases the level or activity of aspartoacylase (ASPA) in the cells of the subject, for the purpose of providing a substrate for mitochondrial oxidative phosphorylation. In some embodiments, the administered composition increases the protein expression level of ASPA in the cells of the subject.

[0007] In some embodiments, the composition comprises a gene therapy composition. In some embodiments, the composition may comprise a nucleic acid encoding ASPA or a functional fragment thereof having an amino acid sequence at least 75%, 85%, 95%, 99% identical to the sequence of SEQ ID NO:1.

[0008] In some embodiments, the method comprises introducing nucleic acid into at least one cell of the subject by viral transduction.The composition can be provided with a virus or virus-like particle that contains the nucleic acid.In some embodiments, the nucleic acid is carried on a recombinant adeno-associated virus (rAAV) vector, such as AAV9.

[0009] In some embodiments, the method includes administering the composition to at least a portion of the subject's spinal cord, hi some embodiments, the composition is administered locally to the portion of the subject's spinal cord.

[0010] In some embodiments, the method further comprises administering a second therapeutic agent to the subject. The second therapeutic agent can be administered to the subject before, after, or simultaneously with the composition. In some embodiments, the second therapeutic agent is riluzole (6-(trifluoromethoxy)-2-benzothiazolamine), or a salt or solvate thereof. In some embodiments, the second therapeutic agent is edaravone (5-methyl-2-phenyl-4H-pyrazol-3-one), or a salt or solvate thereof. In some embodiments, the composition can be administered by a route selected from oral, parenteral, transdermal, pulmonary, intranasal, buccal, intrathecal, and intravenous.

[0011] In some embodiments, the subject is a mammal, such as a human. In some embodiments, the at least one cell is in the spinal cord of the subject. In some embodiments, the subject shows at least one symptom or mutation associated with ALS. In some embodiments, the at least one symptom of ALS is mitochondrial dysfunction. Disruption of mitochondrial structure, dynamics, and bioenergetics has been widely reported in ALS patients and model systems, and has been suggested to be directly involved in the pathogenesis of the disease.

[0012] In some embodiments, administration of the composition will enhance substrates for mitochondrial energy metabolism in the subject. In some embodiments, administration of the composition increases cell survival in the subject. In some embodiments, administration of the composition increases motor neuron survival in the subject. In some embodiments, administration of the composition extends the life expectancy of the subject.

[0013] Also within the scope of this disclosure is a kit for increasing the level or activity of ASPA in a cell of a subject within the scope of this disclosure.The kit comprises a rAAV vector or virus-like particle, and the virus or virus-like particle comprises a nucleic acid encoding ASPA or a functional fragment thereof, the nucleic acid having an amino acid sequence at least 75%, 85%, 95%, or 99% identical to the sequence of SEQ ID NO:1.In some embodiments, the nucleic acid encoding ASPA or a fragment thereof comprises the amino acid sequence of SEQ ID NO:1.In some embodiments, the rAAV vector is AAV9. [Brief description of the drawings]

[0014] For the purpose of illustrating the invention, certain embodiments of the invention are shown in the drawings. However, the invention is not limited to the precise arrangements and instrumentalities of the embodiments shown in the drawings. For data shown in the figures, asterisks indicate the following levels of statistical significance: *p≦0.05, **p≦0.01, and ***p≦0.001.

[0015] [Figure 1] Using established methodology, neurons differentiated in vitro from ALS patient-derived iPSCs after 40 days are shown (Kiskinis et.al., 2014, Cell Stem Cell). Cells are positive for the neuronal marker, TuJ-1, and the motor neuron marker, choline acetyltransferase (ChAT). [Diagram 2] Figure 1 shows restoration of mitochondrial adenosine triphosphate (ATP) synthesis after treatment with AAV-ASPA. Motor neuron cultures generated from ALS iPSCs were transduced in culture at day 28 with adeno-associated viral vectors (AAV) to deliver either ASPA or GFP. At day 40, intact mitochondria were isolated from cells and assayed for ATP synthesis. Naive wild type, non-ALS cells (WT), naive ALS SOD1 mutant cells (ALS), AAV-GFP SOD1 mutant cells (ALS GFP), and AAV-ASPA SOD1 mutant cells (ALS ASPA) were assayed (n=5 / group). A significant 1.5-fold increase in ATP synthesis rate (jiM ATP / min / jig of isolated mitochondria, using 15 jig per reaction) was observed in AAV-ASPA-treated ALS cells compared to AAV-GFP negative controls. **p<0.005, *p<0.05. [Diagram 3] We show that NAA contains acetyl coenzyme A (AcCoA) from glycolysis and aspartate, which is used to transfer cytosolic reducing equivalents (NADH) to the inner mitochondrial membrane. Both are substrates for mitochondrial ATP synthesis, with aspartate playing a key role in coupling glycolysis to oxidative phosphorylation by complexes I-V of the electron transport chain. Thus, liberation of this substrate in neurons affected by neurodegenerative pathologies increases energy conservation. [Figure 4A](collectively "Figure 4") shows targeted neurons for metabolic gene therapy. AAV reporter vector expressing green fluorescent protein (GFP) delivered to the hippocampus of an adult mouse. Figure 4A shows a low magnification confocal microscopy image of a GFP-expressing neuron labeled with an antibody against neuronal nuclear antigen (NeuN). Figure 4B shows a higher magnification of the area highlighted by the white arrow in panel A. Individual GFP-positive cell bodies co-labeled with NeuN (Figure 4C) are shown to emit a merged yellow signal (appearing in a lighter shade in the black and white replica of the image) (Figure 4D), thereby supporting neuronal tropism in vivo. Thus, the therapeutic gene of interest can be delivered to neurons in the mammalian brain to the extent that it can be appropriately packaged using an appropriate AAV. Data were generated using published methodologies (Francis, et al., 2006, Journal of Neuroscience Research 84(1):151-169; Francis, et al., 2011, Glia 59(10):1435-1446). [Figure 4B] (collectively "Figure 4") shows targeted neurons for metabolic gene therapy. AAV reporter vector expressing green fluorescent protein (GFP) delivered to the hippocampus of an adult mouse. Figure 4A shows a low magnification confocal microscopy image of a GFP-expressing neuron labeled with an antibody against neuronal nuclear antigen (NeuN). Figure 4B shows a higher magnification of the area highlighted by the white arrow in panel A. Individual GFP-positive cell bodies co-labeled with NeuN (Figure 4C) are shown to emit a merged yellow signal (appearing in a lighter shade in the black and white replica of the image) (Figure 4D), thereby supporting neuronal tropism in vivo. Thus, the therapeutic gene of interest can be delivered to neurons in the mammalian brain to the extent that it can be appropriately packaged using an appropriate AAV. Data were generated using published methodologies (Francis, et al., 2006, Journal of Neuroscience Research 84(1):151-169; Francis, et al., 2011, Glia 59(10):1435-1446). [Figure 4C] (collectively "Figure 4") shows targeted neurons for metabolic gene therapy. AAV reporter vector expressing green fluorescent protein (GFP) delivered to the hippocampus of an adult mouse. Figure 4A shows a low magnification confocal microscopy image of a GFP-expressing neuron labeled with an antibody against neuronal nuclear antigen (NeuN). Figure 4B shows a higher magnification of the area highlighted by the white arrow in panel A. Individual GFP-positive cell bodies co-labeled with NeuN (Figure 4C) are shown to emit a merged yellow signal (appearing in a lighter shade in the black and white replica of the image) (Figure 4D), thereby supporting neuronal tropism in vivo. Thus, the therapeutic gene of interest can be delivered to neurons in the mammalian brain to the extent that it can be appropriately packaged using an appropriate AAV. Data were generated using published methodologies (Francis, et al., 2006, Journal of Neuroscience Research 84(1):151-169; Francis, et al., 2011, Glia 59(10):1435-1446). [Figure 4D] (collectively "Figure 4") shows targeted neurons for metabolic gene therapy. AAV reporter vector expressing green fluorescent protein (GFP) delivered to the hippocampus of an adult mouse. Figure 4A shows a low magnification confocal microscopy image of a GFP-expressing neuron labeled with an antibody against neuronal nuclear antigen (NeuN). Figure 4B shows a higher magnification of the area highlighted by the white arrow in panel A. Individual GFP-positive cell bodies co-labeled with NeuN (Figure 4C) are shown to emit a merged yellow signal (appearing in a lighter shade in the black and white replica of the image) (Figure 4D), thereby supporting neuronal tropism in vivo. Thus, the therapeutic gene of interest can be delivered to neurons in the mammalian brain to the extent that it can be appropriately packaged using an appropriate AAV. Data were generated using published methodologies (Francis, et al., 2006, Journal of Neuroscience Research 84(1):151-169; Francis, et al., 2011, Glia 59(10):1435-1446). [Diagram 5] This demonstrates targeting synaptic function using gene therapy. Endogenous NAA catabolized by recombinant ASPA delivered by AAV increases substrates for energy metabolism and increases available ATP to support synaptic transmission in neurons. [Figure 6] This shows that the reducing power of NADH generated by cytosolic glycolysis is transported into the mitochondrial inner membrane space by the transfer of hydrogen ions to aspartate by aspartate aminotransferase to generate malate. Aspartate is transferred from mitochondria to the cytosol in exchange for glutamate. Cytosolic aspartate is then converted to malate, which carries the hydrogen ion of cytosolic NADH and is free to move into mitochondria. Once inside, malate is converted back to aspartate by malate dehydrogenase, thereby liberating hydrogen ions to form NADH, which can be utilized to drive mitochondrial oxidative phosphorylation. [Figure 7] We show that free aspartate generated by cleavage of NAA by ASPA becomes available for the malate-aspartate shuttle (MAS), which transfers reduced NADH generated by glycolysis to mitochondria. The NADH thus available drives electron transport chain complexes I–V, culminating in newly synthesized ATP. [Figure 8]Schematic diagram of the methodology for the demonstration of ASPA-generated free aspartate-driven oxidative phosphorylation and ATP synthesis in isolated spinal cord mitochondria. (1) HeLa cells in 60 mm dishes were transfected with plasmids for constitutively expressing wild-type human ASPA (WT) or a non-functional mutant isoform (E285A). (2) Transfected cells were harvested after 48 h and mechanically lysed by sonication. (3) 50 μl of the lysate was added to a reaction mixture containing 5 mM purified NAA and incubated at 37 °C for 2 h to allow the transfected ASPA enzyme to catabolize the NAA substrate. (4) The catabolic reaction was heat inactivated and 50 μl was added to isolated mitochondria in a reaction mix for a luminescence-based ATP synthesis assay. [Figure 9] The rates of ATP synthesis in mitochondria isolated from G93A SOD spinal cords and incubated with reaction mixtures derived from HeLa cells transfected with wild-type ASPA, HeLa cells transfected with E285A ASPA, or saline-treated HeLa cells are shown diagrammatically in Figure 8. Addition of the products of the reaction fueled by wild-type ASPA significantly increased the rate of ATP synthesis proportional to the aspartate content of the aliquot (p=0.039) (see Table 1). [Figure 10] The mean latency in SOD G93A mutant mice treated with either intrathecally administered saline or AAV9-ASPA at 12–16 weeks of age is shown. The average of three individual trials is shown along with the standard error of the mean (n=15 / group). [Figure 11A](collectively "Figure 11") shows HPLC analysis of NAA and adenosine triphosphate (ATP): adenosine monophosphate (AMP) ratio (henceforth, ATP:AMP ratio) in the spinal cord of 16-week-old wild-type, saline-treated SOD, and AAV9-ASPA-treated SOD mice. A). A significant decrease in spinal cord NAA, along with an associated drop in the ATP:AMP ratio (B), is observed in saline SOD mice compared to age-matched wild-type, suggesting a pathological decrease in NAA in response to reduced production of ATP to use (reflected in levels of AMP). Levels of NAA are further decreased in AAV9-ASPA-treated SOD spinal cord, but are associated with a corresponding increase in ATP:AMP, suggesting increased ATP synthesis. [Figure 11B] (collectively "Figure 11") shows HPLC analysis of NAA and adenosine triphosphate (ATP): adenosine monophosphate (AMP) ratio (henceforth, ATP:AMP ratio) in the spinal cord of 16-week-old wild-type, saline-treated SOD, and AAV9-ASPA-treated SOD mice. A). A significant decrease in spinal cord NAA, along with an associated drop in the ATP:AMP ratio (B), is observed in saline SOD mice compared to age-matched wild-type, suggesting a pathological decrease in NAA in response to reduced production of ATP to use (reflected in levels of AMP). Levels of NAA are further decreased in AAV9-ASPA-treated SOD spinal cord, but are associated with a corresponding increase in ATP:AMP, suggesting increased ATP synthesis. [Figure 12]Figure 1 shows ATP synthesis rates in mitochondria isolated from wild-type, saline-treated SOD and AAV9-ASPA-treated SOD spinal cords. Mitochondria were assayed using a commercially available luminescence-based kit. ATP synthesis rates in mitochondria isolated from AAV9-ASPA-transduced SOD spinal cords were significantly superior to saline-treated SOD spinal cord mitochondria, suggesting that the provision of NAA-derived aspartate via ASPA gene therapy is an effective means of enhancing energy metabolism and exhibits associated benefits on motor function in ALS. Mean ATP synthesis rates, + / - standard error presented (n=5 / group). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] The present invention relates, in one aspect, to the unexpected discovery that increased expression of an aminoacylase, such as aspartoacylase (ASPA), in a cell can be used to prevent, treat, or reverse one or more symptoms of ALS in a subject in need thereof. In certain embodiments, the compositions and methods of the present invention treat or prevent mitochondrial dysfunction in an ALS patient. In other embodiments, the compositions and methods of the present invention enhance substrates for energy metabolism in cells affected by ALS. In yet other embodiments, the compositions and methods of the present invention promote cell survival in an ALS patient. In yet other embodiments, the compositions and methods of the present invention promote survival of motor neurons in an ALS patient. In yet other embodiments, overexpression of ASPA in the spinal cord extends life expectancy in an ALS patient. In yet other embodiments, the treatment utilizes patient-derived motor neurons generated from induced pluripotent stem cells (iPSCs). In yet other embodiments, the treatment utilizes stem cells, progenitor cells, or patient-derived induced pluripotent stem cells (iPSCs) engineered to overexpress ASPA (or a functional fragment thereof) for transplantation into the affected area of ​​the patient's nervous system. In still other embodiments, the expression of ASPA and the construction of delivery construct are carried out ex vivo.In some embodiments, the expression of ASPA can show a reduced degeneration rate of ex vivo human muscle tissue explants compared with that of ALS subjects.In another embodiment, the treatment is a one-time gene therapy for ALS and related disorders.

[0017] Although the pathogenesis of major neurodegenerative diseases is multifactorial and not fully defined, therapeutic strategies that enhance mitochondrial integrity have the potential to slow the progressive loss of higher functions. In the case of ALS in particular, mitochondrial dysfunction is thought to be directly or indirectly linked to all the assumed toxic mechanisms associated with ALS, such as excitotoxicity, loss of protein homeostasis, and defects in axonal transport. Despite the differences in the assumed pathogenic mechanisms in the different in vitro and in vivo models studied, reduced mitochondrial electron transport chain (ETC) activity and ATP levels appear as common features in both familial and sporadic ALS.

[0018] The present invention provides a novel gene therapy intervention to provide ALS neurons with access to a specific energy substrate sequestered within the endogenous amino acid derivative, N-acetylaspartate (NAA) (Figure 3). NAA normally functions to conserve ATP in white matter-producing glial cells by uncoupling lipid synthesis from oxidative phosphorylation via the provision of AcCoA through catabolism by the glial hydrolase ASPA. Neurons do not naturally express ASPA and therefore cannot catabolize NAA. Catabolism of NAA by ASPA results in free acetate (used by glia to synthesize AcCoA) and aspartate. Unlike acetate, neuronal aspartate is a specific substrate for subunits of the malate-aspartate shuttle (Aralar1) and is therefore an essential component of the shuttle machinery for the transfer of glycolytic reducing equivalents to mitochondria (Figure 3). Free acetate is a poor substrate for neuronal energy metabolism because, compared to glial cells, there are relatively few available biochemical mechanisms that can process acetate for energy metabolism, and acetate cannot substitute for glucose in supporting neuronal function. Analysis of the flux of radiolabeled acetate provided to the nervous system has indeed demonstrated a predominant use by glial cells compared to neurons, and acetate is not involved in the transfer of cytosolic NADH to the mitochondrial ETC by Aralar1, a process that requires the conversion of aspartate to malate in the cytosol. In certain non-limiting embodiments, providing neurons with the ability to catabolize endogenous NAA promotes spare ATP conservation in the face of pathological metabolic abnormalities by providing aspartate for the shuttle of glycolytic reducing equivalents to mitochondria. In at least one embodiment, the present invention relates to a method of increasing the availability of aspartate for the shuttle of glycolytic reducing equivalents to mitochondria in a subject at risk of developing ALS or suffering from ALS.

[0019] Adeno-associated virus (AAV) has emerged as a very promising and attractive approach to gene delivery with an established clinical safety and efficacy profile, and is highly efficient in targeting neurons. Advances in AAV vector design and associated administration techniques have enabled widespread gene delivery in the brain and spinal cord, making AAV highly suitable for the treatment of neurodegenerative diseases. In at least one embodiment, the present invention uses an AAV serotype to deliver a gene therapy composition comprising a nucleic acid encoding ASPA or a functional fragment thereof, having an amino acid sequence at least 75%, 85%, 95%, 99% identical to the sequence of SEQ ID NO:1.

[0020] The present disclosure has shown that expression of aminoacylase in motor neurons of the spinal cord of an ALS mouse model results in long-term improvement in motor function, as measured by accelerating rotarod performance in SOD(G93A) transgenic mice. The improved rotarod performance was associated with an increase in detectable spinal cord energy currency (ATP) and an associated increase in detectable free aspartate. This result suggested a mechanistic link between aspartate bioavailability and mitochondrial function and ETC function and energy currency generation in the face of ALS pathology. Specifically, the provision of extra bioavailable aspartate due to increased ASPA activity has been shown to promote the activity of the malate-aspartate shuttle, in which aspartate is rate-limiting, to generate energy currency in the form of ATP. In at least one embodiment, the methodology of the present invention increases the bioavailability of aspartate in the spinal cord of a subject at risk of developing ALS or suffering from ALS.

[0021] In one aspect, the present disclosure provides a method for treating, improving, or reversing at least one symptom of amyotrophic lateral sclerosis (ALS) in a subject in need thereof.The method comprises administering to the subject a therapeutically effective amount of a composition that increases the level or activity of aspartoacylase (ASPA) in the cells of the subject.In some embodiments, the administered composition increases the protein expression level of ASPA in the cells of the subject.In yet another embodiment, the method of the present invention relates to increasing NAA catabolism in the spinal cord of a patient suffering from ALS.

[0022] In another embodiment, the subject in need of the treatment of the present invention is a subject who has experienced a decline in motor function or is at risk of experiencing motor function impairment with a pathology different from cognitive impairment. In another embodiment, a subject who is at risk of motor impairment and exhibits a hypermetabolic state that may show a metabolic ratio of more than 1 when measured based on the Harris and Benedict formula is a candidate for the proposed intervention. In another embodiment, a subject in need may exhibit defects related to the motor neurons of the spinal cord that have high metabolic demands for the maintenance of action potentials that may not be presented by other diseases that do not primarily affect the motor system. In other embodiments, a subject in need may exhibit gradual onset, painless, progressive muscle weakness accompanied by stumbling, dropping things, abnormal fatigue of the arms and / or legs, slurred speech, muscle spasms and twitches, and / or periods of uncontrollable laughing or crying. In some embodiments, a subject suffering from respiratory muscle weakness may require permanent ventilatory support to assist breathing.

[0023] In other embodiments, the subject in need of the treatment of the present invention may exhibit a mutation that may be critical in the proper diagnosis and onset of ALS, including, for example, mutations in ALS2 (arsin), TBK1 (TANK-binding kinase 1), TUBA4A (tubulin, alpha 4A), ANG (angiogenin), MATR3 (matrin-3), CHCHD10 (coiled-coil helix coiled-coil helix domain-containing 10), NEK1, PFN1 (profilin-1), C21ORF2, MOBP, SCFD1, SETX (senataxin), FUS, TDP43, VCP (valosin-containing protein), or enzymes associated with ALS (e.g., KIF5A, inesin family member 5A), and OPTN (optineurin). In another embodiment, the mutation may be in the C9ORF72 gene or may cause the accumulation of RNA that occurs when the gene is mutated. In yet another embodiment, the subject may first be screened for the presence of such a mutation. Moreover, in some embodiments, the screen is to identify at least any two or more of the above identified mutations.

[0024] In another embodiment, the present invention relates to administering therapeutically effective gene therapy drugs to subjects who show mutations in ALS2, TBK1, TUBA4A, ANG, MATR3, CHCHD10, NEK1, PFN1, C21ORF2, MOBP, SCFD1, SETX, FUS, TDP43, VCP, or OPTN. In yet another aspect, suitable screened subjects can be administered gene therapy compositions comprising nucleic acids encoding ASPA or functional fragments thereof, having an amino acid sequence at least 75%, 85%, 95%, or 99% identical to the sequence of SEQ ID NO: 1. In another embodiment, identified subjects can be administered gene therapy compositions comprising SEQ ID NO: 1 and AAV-9, and exhibit increased levels of NAA catabolism in the spinal cord. In at least one embodiment, the invention relates to administering the disclosed gene therapy agents to patients exhibiting clinical symptoms of ALS, and to patients exhibiting ALS symptoms that may exhibit mutations in TBK1, TUBA4A, NEK1, C21ORF2, MOBP, SCFD1, FUS, and TDP43, or any combination of such mutations, by identifying at least one of the above-mentioned genetic mutations or genetic mutations occurring in proteins involved in cell axon dynamics and proteins involved in cell clearance mechanisms.

[0025] In at least one embodiment, the present invention relates to administering a genetic therapy agent of the present invention to a subject exhibiting a mutation in Cu / Zn superoxide dismutase (SOD1), in particular to increase the level of NAA catabolism in the spinal cord mitochondria of such patients exhibiting at least one clinical symptom of ALS. It has been suggested that only 5-10% of familial ALS cases have a genetic origin (familial ALS), and only about 20% of familial ALS cases have a mutation in Cu / Zn superoxide dismutase (SOD1). Mutations in SOD1 associated with ALS cause a decrease in protein stability. These mutations occur throughout the protein structure, including the active site, beta sheets, and monomer interfaces. To this end, at least one embodiment of the present invention relates to a method of administering a genetic therapy agent of the present invention to a patient exhibiting an SOD1 mutation. In yet another embodiment, the present invention relates to a method comprising identifying a subject having an SOD1 mutation, administering to said subject a composition comprising a nucleic acid encoding ASPA or a fragment thereof, the composition comprising the amino acid sequence of SEQ ID NO: 1 and AAV-9, and increasing the level of NAA catabolism in the spinal cord of such a subject.

[0026] In other embodiments, the subject in need of this invention shows upper and lower motor neuron degeneration with or without progressive brainstem degeneration, decreased neurological status, or muscle weakness after electromyography (EMG) testing, compared with healthy patients.However, such patients do not show decreased dopamine receptor occupancy, do not respond to administration of L-dopa, and such subjects do not show symptoms related to cognitive loss, such as patients suffering from Alzheimer's disease.

[0027] In some embodiments, the composition comprises a gene therapy composition. In some embodiments, the composition may comprise a nucleic acid encoding ASPA or a functional fragment thereof, the nucleic acid having an amino acid sequence at least 75%, 85%, 95%, or 99% identical to the sequence of SEQ ID NO: 1. In some embodiments, the nucleic acid encoding ASPA or a fragment thereof comprises the amino acid sequence of SEQ ID NO: 1. [Table 1]

[0028] Also included within the scope of the present disclosure are variants, mutants, and homologs that have significant identity with ASPA.For example, such variants and homologs have at least about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% sequence identity with the sequence of ASPA described herein.

[0029] The terms "variant" and "mutant" when used in reference to a polypeptide refer to an amino acid sequence that differs from another, normally related polypeptide in one or more amino acids. A variant may have "conservative" changes, in which the substituted amino acid has similar structural or chemical properties. Certain conservative amino acid substitutions refer to the interchangeability of residues with similar side chains. For example, a group of amino acids with aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids with aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids with amide-containing side chains is asparagine and glutamine; a group of amino acids with aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids with basic side chains is lysine, arginine, and histidine; a group of amino acids with sulfur-containing side chains is cysteine ​​and methionine. Preferred conservative amino acid substitutions are valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine. Rarely, variants can have "non-conservative" changes (e.g., replacement of glycine with tryptophan). Similar minor changes can also include amino acid deletions or insertions (i.e., additions), or both. Guidance for determining which and how many amino acid residues can be substituted, inserted, or deleted without losing biological activity can be found using computer programs well known in the art, such as DNAStar software. Variants can be tested in functional assays. Preferred variants have less than 10% changes (substitutions, deletions, etc.), preferably less than 5%, and even more preferably less than 2%.

[0030] The term "homolog" or "homology", when used in reference to a polypeptide, refers to a high degree of sequence identity between two polypeptides, or a high degree of similarity between the three-dimensional structures, or a high degree of similarity between the active sites and the mechanism of action. In a preferred embodiment, a homolog has more than 60% sequence identity, more preferably more than 75% sequence identity, and even more preferably more than 90% sequence identity with a reference sequence. The term "substantial identity" as applied to a polypeptide means that two peptide sequences share at least 75% sequence identity when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights.

[0031] As used herein, expressing a gene means that the cell produces either the full-length polypeptide encoded by the gene or a functional fragment of the full-length polypeptide. The term "functional", when used in conjunction with "fragment", refers to a polypeptide that has a biological activity substantially similar to the biological activity of the entity or molecule of which it is a fragment. "Substantially similar" in this context means that at least 25%, at least 35%, at least 50% of the relevant or desired biological activity of the corresponding wild-type peptide is retained. For example, a functional fragment of a polypeptide retains an enzymatic activity substantially similar to that of the full-length polypeptide encoded by the gene expressed in the cell.

[0032] "Overexpression" refers to the production of a gene product in a cell / organism that exceeds the level of production in a normal or non-transformed cell / organism. For example, it can refer to an elevated (e.g., abnormal) level of mRNA encoding a protein(s) (e.g., ASPA protein or a homolog thereof) and / or an elevated level of a protein(s) (e.g., ASPA) when compared to a similar corresponding unmodified cell / organism that expresses a basal level of mRNA (e.g., encoding ASPA protein) or has a basal level of protein. In certain embodiments, ASPA or a homolog thereof can be overexpressed by at least 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 8-fold, 10-fold, 12-fold, 15-fold, or more in a cell / organism designed to exhibit increased mRNA, protein, and / or activity of ASPA.

[0033] Expression of ASPA can be induced by introducing one or more expression vectors carrying a nucleic acid encoding one or more of the ASPA polypeptides or fragments thereof. The polypeptides or fragments thereof can be inserted into the appropriate site of the vector (e.g., operably linked to a promoter). The expression vectors are introduced into the selected host cells for amplification and / or polypeptide expression by well-known methods such as transfection, transduction, infection, electroporation, microinjection, lipofection, or the DEAE-dextran method or other known techniques. These and other suitable methods are well known to those of skill in the art.

[0034] A wide variety of vectors can be used to express ASPA proteins. The ability of certain viruses to infect or enter cells by receptor-mediated endocytosis and to integrate into the host cell genome to stably and efficiently express viral genes makes them attractive candidates for transferring foreign nucleic acids into cells. Thus, in certain embodiments, viral vectors are used to introduce nucleotide sequences encoding ASPA proteins or fragments thereof into host cells for expression. Viral vectors can include nucleotide sequences encoding ASPA proteins or fragments thereof operably linked to one or more control sequences, such as promoters. Alternatively, viral vectors may not include control sequences and instead rely on control sequences in the host cell to drive the expression of ASPA proteins or fragments thereof. Non-limiting examples of viral vectors that can be used to deliver nucleic acids include adenoviral vectors, AAV vectors, and retroviral vectors.

[0035] For example, adeno-associated virus (AAV) can be used to introduce the nucleotide sequence encoding ASPA protein or its fragment into host cell for expression.AAV system has been described previously and is generally known in the art (Kelleher and Vos, Biotechniques, 17(6):1110-7, 1994; Cotten et al., Proc Natl Acad Sci USA, 89(13):6094-6098, 1992; Curiel, Nat Immun, 13(2-3):141-64, 1994; Muzyczka, Curr Top Microbiol Immunol, 158:97-129, 1992).The details of the generation and use of rAAV vectors are described in, for example, U.S. Patent No. 5,139,941 and U.S. Patent No. 4,797,368, each of which is incorporated herein by reference in its entirety for all purposes.

[0036] In some embodiments, retroviral expression vectors can be used to introduce the nucleotide sequence encoding ASPA protein or its fragments into host cells for expression.These systems have been described previously and are generally known in the art (Nicolas and Rubinstein, In: Vectors: A survey of molecular cloning vectors and their uses, Rodriguez and Denhardt, eds., Stoneham: Butterworth, pp.494-513, 1988; Temin, In: Gene Transfer, Kucherlapati (ed.), New York: Plenum Press, pp.149-188, 1986).Examples of vectors for eukaryotic expression in mammalian cells include AD5, pSVL, pCMV, pRc / RSV, pcDNA3, Pbpv, etc., using promoters such as CMV, SV40, EF-1, UbC, RSV, ADV, BPV, β-actin, etc., and vectors derived from viral systems such as vaccinia virus, adeno-associated virus, herpes virus, retrovirus, etc.

[0037] Combinations of retroviruses with appropriate packaging lines may also be useful, where the capsid protein functions to infect target cells. Typically, cells and virus are cultured in culture medium for at least about 24 hours. Cells are then grown in culture medium for a short period of time, e.g., 24-73 hours, or at least 2 weeks in some applications, and may be grown for 5 weeks or more before analysis. Commonly used retroviral vectors are "defective," i.e., unable to produce viral proteins necessary for productive infection. Replication of the vector requires growth in a packaging cell line. The host cell specificity of retroviruses is determined by the envelope protein env(pl20). The envelope protein is provided by the packaging cell line. There are at least three types of envelope proteins: ecotropic, amphotropic, and xenotropic. Retroviruses packaged with ecotropic envelope proteins, e.g., MMLV, are capable of infecting most mouse and rat cell types. Ecotropic packaging cell lines include BOSC23. Retroviruses with amphotropic envelope proteins, such as 4070A, can infect most mammalian cell types, including human, dog, and mouse. Amphotropic packaging cell lines include PA12 and PA317. Retroviruses packaged with xenotropic envelope proteins, such as AKR env, can infect most mammalian cell types, except mouse cells. The vectors may contain genes that must be subsequently removed, for example, using a recombinase system such as Cre / Lox, or cells expressing them are destroyed by including genes that allow selective toxicity, for example, herpesvirus TK, bcl-xs, etc. An appropriate inducible promoter is activated in the desired target cell type, either the transfected cell or its progeny.

[0038] In some embodiments, genome editing techniques such as CRISPR / Cas9 system, designer zinc finger, transcription activator-like effector (TALE), or homing meganuclease can be used to induce the expression of the described ASPA protein in cells.In general, "CRISPR / Cas9 system" refers collectively to the transcripts and other elements involved in the expression of CRISPR-associated ("Cas") genes or inducing their activity, including sequences encoding Cas genes, tracr (transactivating CRISPR) sequences (e.g., tracrRNA or active partial tracrRNA), tracr-mate sequences (including "direct repeats" and partial direct repeats processed by tracrRNA with respect to endogenous CRISPR systems), guide sequences (also referred to as "spacers" with respect to endogenous CRISPR systems), or other sequences and transcripts from CRISPR loci.One or more elements of the CRISPR system can be derived from type I, type II, or type III CRISPR systems. Alternatively, one or more elements of the CRISPR system can be derived from a particular organism that contains an endogenous CRISPR system, such as Streptococcus pyogenes.Generally, CRISPR systems are characterized by an element (also referred to as a protospacer for endogenous CRISPR systems) that promotes the formation of CRISPR complexes at the site of target sequence.In some embodiments, genome editing techniques such as CRISPR / Cas9 system, designer zinc finger, transcription activator-like effector (TALE), or homing meganuclease can be used to induce the expression of the described ASPA protein in cells, increasing the substrate for mitochondrial oxidative phosphorylation.

[0039] In some embodiments, the method comprises introducing nucleic acid into at least one cell of the subject by viral transduction.The composition can be provided with a virus or virus-like particle that contains the nucleic acid.In some embodiments, the nucleic acid is carried by a recombinant adeno-associated virus (rAAV) vector, such as AAV9.

[0040] In some embodiments, rAAV is artificially generated from its natural environment (e.g., from a host cell, tissue, or subject). For example, isolated AAV can be generated using recombinant methods. Such rAAV preferably has tissue-specific targeting ability, such that AAV transgene is specifically delivered to one or more predetermined tissues. AAV capsid is an important factor in determining their tissue-specific targeting. For this reason, in at least one embodiment, recombinant AAV with capsid suitable for spinal cord tissue can be selected. Methods for obtaining recombinant AAV with desired capsid proteins are described, for example, in Patent Application Publication No. 2003 / 0138772, the entirety of which is incorporated herein by reference.

[0041] In another aspect, the present invention provides a method for treating, ameliorating, or reversing at least one symptom of ALS in a subject in need thereof by identifying a patient in need of increasing intracellular aspartate levels, the method comprising administering to the subject a therapeutically effective amount of a composition that increases the level or activity of aspartoacylase (ASPA) in at least one cell of the subject, the composition comprising a nucleic acid encoding ASPA or a functional fragment thereof having an amino acid sequence at least 75% identical to the sequence of SEQ ID NO:1.

[0042] In some embodiments, the method includes administering the composition to at least a portion of the spinal cord of the subject. In some embodiments, the composition is administered locally to a portion of the spinal cord of the subject. In some embodiments, the composition can be administered to the brainstem for use in treating ALS. In another embodiment, the composition of the present invention for use in treating ALS can be combined with a second pharmaceutical compound to treat or slow the progression of upper and lower motor neuron degeneration or improve upper and lower motor function. In some embodiments, the second pharmaceutical compound can be R(+)-N-propargyl-1-aminoindan in combination with 2-amino-6-trifluoromethoxybenzothiazole or their respective pharma- ceutically acceptable salts, including but not limited to mesylate, maleate, fumarate, tartrate, hydrochloride, hydrobromide, esylate, p-toluenesulfonate, benzoate, acetate, phosphate and sulfate.

[0043] Gene Therapy: Nucleic acids encoding the protein(s) useful within the present invention may be used in gene therapy protocols for the treatment of diseases or disorders contemplated herein, such as diseases characterized by energy deficiency in cells of the central and peripheral nervous systems that support motor function, including upper and lower motor neurons of the brain and spinal cord. In certain embodiments, the disease or disorder comprises amyotrophic lateral sclerosis (aggregation of superoxide dismutase). The improved constructs encoding the protein(s) may be inserted into an appropriate gene therapy vector and administered to a patient to treat or prevent the disease or disorder.

[0044] Vectors, such as viral vectors, have been used in the prior art to introduce genes into a wide variety of different target cells. Typically, the vector is exposed to the target cells so that transformation can occur at a rate sufficient to provide a useful therapeutic or prophylactic effect from the expression of a desired polypeptide (e.g., a receptor). The transfected nucleic acid may be permanently integrated into the genome of each of the target cells, providing a long-term effect, or the treatment may have to be repeated periodically.

[0045] A variety of vectors, both viral and plasmid vectors, are known in the art (see, for example, U.S. Pat. No. 5,252,479 and WO93 / 07282). In particular, many viruses have been used as gene transfer vectors, including parvoviruses such as SV40, vaccinia viruses, herpes viruses including HSV and EBV, and retroviruses. Many gene therapy protocols in the prior art use defective murine retroviruses. Several recently issued patents relate to methods and compositions for carrying out gene therapy (see, for example, U.S. Pat. Nos. 6,168,916, 6,135,976, 5,965,541 and 6,129,705). Each of the aforementioned patents is incorporated herein in its entirety by reference.

[0046] AAV-mediated gene therapy: AAV, a parvovirus belonging to the Dependovirus genus, has several characteristics that make it particularly suitable for gene therapy applications. For example, AAV can infect a wide range of host cells, including non-dividing cells. Furthermore, AAV can infect cells of various species. Importantly, AAV is not associated with any human or animal disease and is not thought to alter the physiological properties of host cells upon integration.

[0047] Finally, AAV is stable under a wide range of physical and chemical conditions, making it suitable for manufacturing, storage, and transportation requirements. The AAV genome, a linear, single-stranded DNA molecule containing approximately 4,700 nucleotides (the AAV-2 genome consists of 4,681 nucleotides, and the AAV-4 genome consists of 4,767), generally contains an internal non-repetitive segment flanked at both ends by inverted terminal repeats (ITRs). The ITRs are approximately 145 nucleotides long (AAV-1 has an ITR of 143 nucleotides) and have multiple functions, including functioning as origins of replication and as packaging signals for the viral genome. The internal non-repetitive portion of the genome contains two large open reading frames (ORFs) known as the AAV replication (rep) and encapsidation (cap) regions. These ORFs encode the replication and encapsidation gene products, allowing the replication, assembly, and packaging of complete AAV virions. More specifically, at least four families of viral proteins are expressed from the AAV rep region: Rep78, Rep68, Rep52, and Rep40, all named for their apparent molecular weight. The AAV cap region encodes at least three proteins: VP1, VP2, and VP3. AAV is a helper-dependent virus, i.e., it requires co-infection with a helper virus (e.g., adenovirus, herpesvirus, or vaccinia virus) to form a functionally complete AAV virion. In the absence of co-infection with a helper virus, AAV inserts the viral genome into the host cell chromosome or establishes a latent state in which the viral genome exists in an episomal form, but no infectious virions are produced.

[0048] Subsequent infection with a helper virus "rescues" the integrated genome, allowing it to replicate and be packaged into a viral capsid, thereby reconstituting an infectious virion. Although AAV can infect cells of different species, the helper virus must be of the same species as the host cell. Thus, for example, human AAV replicates in canine cells co-infected with canine adenovirus.

[0049] To generate infectious recombinant AAV (rAAV) containing heterologous nucleic acid sequences, suitable host cell lines can be transfected with AAV vectors that contain heterologous nucleic acid sequences but lack AAV helper function genes, rep and cap. AAV helper function genes can then be provided in another vector. Also, instead of providing a replication-competent helper virus (such as adenovirus, herpesvirus, or vaccinia), only the helper virus genes (i.e., accessory function genes) required for AAV production can be provided in the vector.

[0050] In summary, AAV helper function genes (i.e., rep and cap) and accessory function genes can be provided in one or more vectors. The helper and accessory function gene products can then be expressed in a host cell, where they act in trans in the rAAV vector containing the heterologous nucleic acid sequence. The rAAV vector containing the heterologous nucleic acid sequence is then replicated and packaged as if it were a wild-type (wt) AAV genome, forming a recombinant virion. When the patient's cells are infected with the resulting rAAV virion, the heterologous nucleic acid sequence enters and is expressed in the patient's cells. Because the patient's cells lack the rep and cap genes, as well as the accessory function genes, the rAAV cannot further replicate and package their genome. Furthermore, without a source of rep and cap genes, wtAAV cannot form in the patient's cells.

[0051] In one embodiment of the invention, suitable AAV serotypes or serotype variants include AAV1 through AAV12, such as AAV2, AAV2.5, AAV5, AAV6, AV6.2, AAV7, AAV8, AAV9, AAV10, AAV11, and AAV12, as well as their capsid variants of AAV-based vectors, such as rationally engineered AAV9HR.

[0052] AAV-1 through AAV-11 have been described in the art (Mori, et al., 2004, Virology 330(2):375-83). AAV-2 is the most common serotype in the human population. One study estimated that at least 80% of the general population is infected with wt AAV-2 (Berns and Linden, 1995, Bioessays 17:237-245). AAV-3 and AAV-5 are also common in the human population, with infection rates of up to 60% (Georg-Fries, et al., 1984, Virology 134:64-71). AAV-1 and AAV-4 are monkey isolates, but both serotypes can transduce human cells (Chiorini, et al., 1997, J Virol 71:6823-6833; Chou, et al., 2000, Mol Ther 2:619-623). Of the six known serotypes, AAV-2 is the best characterized. For example, AAV-2 has been used in a wide range of in vivo transduction experiments and has been shown to transduce different tissue types, including: mouse (U.S. Pat. No. 5,858,351; U.S. Pat. No. 6,093,392), dog muscle; mouse liver (Couto, et al., 1999, Proc. Natl. Acad. Sci. USA 96:12725-12730; Couto, et al., 1997, J. Virol. 73:5438-5447; Nakai, et al., 1999, J. Virol. 73:5438-5447; and Snyder, et al., 1997, Nat. Genet. 16:270-276); mouse heart (Su, et al., 2000, Proc. Natl. Acad. Sci. USA 97:13801-13806); rabbit lungs (Flotte, et al., 1993, Proc. Natl. Acad. Sci. USA 90:10613-10617); and rodent photoreceptors (Flannery et al., 1997, Proc. Natl. Acad. Sci. USA 94:6916-6921).

[0053] The broad tissue tropism of AAV-2 can be exploited to deliver tissue-specific transgenes. For example, AAV-2 vectors have been used to deliver the following genes: the cystic fibrosis transmembrane conductance regulator gene to rabbit lungs (Flotte, et al., 1993, Proc. Natl. Acad. Sci. USA 90:10613-10617); the factor NIII gene (Burton, et al., 1999, Proc. Natl. Acad. Sci. USA 96:12725-12730) and the factor IX gene (Nakai, et al., 1999, J. Virol. 73:5438-5447; Snyder, et al., 1999, J. Virol. 73:5438-5447). al., 1997, Nat. Genet. 16:270-276; U.S. Patent No. 6,093,392) into mouse liver, dog, and mouse muscle (U.S. Patent No. 6,093,392); erythropoietin gene into mouse muscle (U.S. Patent No. 5,858,351); vascular endothelial growth factor (VEGF) gene into mouse heart (Su, et al., 2000, Proc. Natl. Acad. Sci. USA 97:13801-13806); and aromatic 1-amino acid decarboxylase gene into monkey neurons. Expression of transgenes delivered by certain rAAVs has therapeutic effects in experimental animals: for example, expression of factor IX has been reported to restore phenotypic normality in a dog model of hemophilia B (U.S. Patent No. 6,093,392). Furthermore, expression of NEGF delivered by rAAV to mouse myocardium results in neovascularization (Su, et al., 2000, Proc. Natl. Acad. Sci. USA 97:13801-13806). al., 2000, Proc. Natl. Acad. Sci. USA 97:13801-13806), and expression of AADC delivered by rAAV to the brains of monkeys with Parkinson's disease resulted in restoration of dopaminergic function.

[0054] The delivery of the protein to the cells of a mammal is achieved by first generating an AAV vector containing the DNA encoding the protein, and then administering the vector to a mammal. Therefore, the present invention should be interpreted as including the AAV vector containing the DNA encoding the protein. Upon understanding the present invention, the generation of AAV vectors containing the DNA encoding these proteins will be clear to those skilled in the art.

[0055] In certain embodiments, the rAAV vector of the present invention comprises several essential DNA elements. In certain embodiments, these DNA elements include at least two copies of the AAV ITR sequence, promoter / enhancer elements, transcription termination signals, any necessary 5' or 3' untranslated regions adjacent to the DNA encoding the protein or biologically active fragment thereof. The rAAV vector of the present invention may also comprise a portion of the intron of the protein. Optionally, the rAAV vector of the present invention also comprises the DNA encoding the mutant protein.

[0056] In certain embodiments, the vector comprises a promoter / regulatory sequence comprising a promiscuous promoter that can drive high levels of expression of heterologous genes in many different cell types. Such promoters include, but are not limited to, cytomegalovirus (CMV) immediate early promoter / enhancer sequences, Rous sarcoma virus promoter / enhancer sequences, and the like. In certain embodiments, the promoter / regulatory sequence in the rAAV vector of the present invention is a CMV immediate early promoter / enhancer. However, the promoter sequence used to drive expression of heterologous genes can also be an inducible promoter, such as, but not limited to, a steroid-inducible promoter, or a tissue-specific promoter, such as, but not limited to, the skeletal actin promoter and muscle creatine kinase promoter / enhancer, which are specific for muscle tissue.

[0057] In certain embodiments, the rAAV vectors of the invention comprise a transcription termination signal. Although any transcription termination signal can be included in the vectors of the invention, in certain embodiments, the transcription termination signal is an SV40 transcription termination signal.

[0058] In certain embodiments, the rAAV vector of the present invention comprises an isolated DNA encoding the protein of interest or a biologically active fragment of the protein of interest. The present invention should be construed to include any mammalian sequence of the protein of interest, either known or unknown. Thus, the present invention should be construed to include genes from mammals other than humans, whose proteins function in a manner substantially similar to that of the human protein. Preferably, the nucleotide sequence comprising the gene encoding the protein of interest is about 50% homologous to the gene encoding the protein of interest, more preferably about 70% homologous, even more preferably about 80% or 85% homologous, and most preferably about 90%, 95%, or 99% homologous.

[0059] Furthermore, the present invention should be construed to include naturally occurring variants or recombinantly derived mutants of the wild-type protein sequence, which variants or mutants render the proteins encoded thereby as therapeutically effective as the full-length proteins in the gene therapy methods of the present invention, or more therapeutically effective than the full-length proteins.

[0060] The present invention should also be construed to include DNA encoding variants that retain the biological activity of the protein. Such variants include proteins or polypeptides that have been or can be modified using recombinant DNA technology, so that the protein or polypeptide has additional properties that enhance its suitability for use in the methods described herein, for example, but not limited to, the variant confers enhanced stability to the protein in plasma and high specific activity of the protein. Analogs may differ from naturally occurring proteins or peptides by conservative amino acid sequence differences, or by modifications that do not affect sequence, or both. For example, conservative amino acid changes may be made, which change the primary sequence of the protein or peptide, but do not usually change its function.

[0061] The present invention is not limited to the particular rAAV vectors exemplified in the Examples, but rather should be construed to include any suitable AAV vector, including but not limited to vectors based on AAV-1, AAV2.5, AAV-3, AAV-4, AAV-5, AAV-6, AAV-8, AAV-9, etc.

[0062] The invention also includes a method of treating a mammal having a disease or disorder, comprising administering to the mammal an rAAV vector comprising the protein of interest in an amount effective to provide a therapeutic benefit, preferably the mammal is a human.

[0063] Typically, the number of viral vector genomes / mammal administered in a single injection is approximately 1 x 10 8 ~Approx. 5×10 16 Preferably, the number of viral vector genomes / mammal administered in a single injection is in the range of about 1×10 10 ~Approx. 1×10 15 and more preferably, the number of viral vector genomes / mammal administered in a single injection is about 5×10 10 ~Approx. 5×10 15and most preferably, the number of viral vector genomes administered to a mammal in a single injection is about 5×10 11 ~Approx. 5×10 14 It is.

[0064] When the methods of the invention involve multiple site simultaneous injections, or several multiple site injections, including injections at different sites over a period of several hours (e.g., from less than about 1 hour to about 2 or 3 hours), the total number of viral vector genomes administered can be the same as, or a fraction or multiple thereof, of those recited in the single site injection method.

[0065] For administration of the rAAV vector of the present invention in a single site injection, in certain embodiments, the composition containing the virus is directly injected into the subject's brain. For administration to mammals, the rAAV vector can be suspended in a pharmaceutically acceptable carrier, for example, HEPES-buffered saline at a pH of about 7.8. Other useful pharmaceutically acceptable carriers include, but are not limited to, glycerol, water, saline, ethanol, and other pharmaceutically acceptable salt solutions, such as phosphates and salts of organic acids. Examples of these and other pharmaceutically acceptable carriers are described in Remington's Pharmaceutical Sciences (1991, Mack Publication Co., New Jersey).

[0066] The rAAV vectors of the invention may also be provided in the form of a kit comprising, for example, a lyophilized preparation of the vector in a dry salt formulation, sterile water for suspension of the vector / salt composition, and instructions for suspension of the vector and its administration to a mammal.

[0067] Combination therapy The compositions identified using the methods described herein are useful in the methods of the invention in combination with one or more additional compounds or compositions useful in treating the diseases or alleviating the symptoms of the disorders contemplated herein. These additional compounds may include compounds identified herein or compounds known to treat, prevent, or alleviate the symptoms of the diseases or disorders contemplated herein, e.g., commercially available compounds.

[0068] Non-limiting examples of additional compounds include riluzole, edaravone, or their salts or solvates, or combinations thereof.Other compounds, including selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine, alone or in combination with dextromethorphan, and / or quinidine, can also be used in combination with the gene therapy regimen of the present invention.Thus, synergistic effect can be calculated using suitable methods, such as, for example, the Sigmoid-Emax equation (Holford&Scheiner,19981,Clin.Pharmacokinet.6:429-453), the Loewe additivity equation (Loewe&Muischnek,1926,Arch.Exp.Pathol Pharmacol.114:313-326) and the median effect equation (Chou&Talalay,1984,Adv.Enzyme Regul.22:27-55). Each of the above equations can be applied to experimental data to generate corresponding graphs to aid in evaluating the effect of drug combinations. The corresponding graphs associated with the above equations are the concentration-effect curve, the isobologram curve, and the combination index curve, respectively.

[0069] Pharmaceutical Compositions and Formulations: The present invention also includes the use of the pharmaceutical composition of the present invention for carrying out the method of the present invention.Such pharmaceutical composition can be provided in a form suitable for administration to a subject, and can include one or more pharma-ceutically acceptable carriers, one or more additional components, or some combination thereof.At least one composition of the present invention can include physiologically acceptable salts of the compounds contemplated within the present invention, etc., in combination with physiologically acceptable cations or anions, as is well known in the art.

[0070] In one embodiment, pharmaceutical compositions useful for practicing the methods of the invention may be administered to deliver a dose of 1 ng / kg / day to 100 mg / kg / day. In another embodiment, pharmaceutical compositions useful for practicing the invention may be administered to deliver a dose of 1 ng / kg / day to 500 mg / kg / day.

[0071] The relative amounts of the active ingredient, pharma- ceutically acceptable carrier, and any additional ingredients in a pharmaceutical composition of the invention will vary depending on the identity, size, and condition of the subject being treated, as well as the route by which the composition is administered. By way of example, the composition may contain 0.1%-100% (w / w) active ingredient.

[0072] Pharmaceutical compositions useful in the methods of the present invention may be suitably developed for inhalation, oral, rectal, vaginal, parenteral, topical, transdermal, pulmonary, intranasal, buccal, ophthalmic, intrathecal, intracranial, intravenous or another route of administration. Other contemplated formulations include contemplated nanoparticles, liposomal preparations, resealed red blood cells containing the active ingredient, and immunologically-based formulations. The route(s) of administration will be readily apparent to those skilled in the art and will depend on any number of factors, including the type and severity of the disease being treated, the type and age of the animal or human patient being treated, and the like. The formulations of the pharmaceutical compositions described herein can be prepared by any method known or hereafter developed in the art of pharmacology. In general, such preparation methods include the steps of bringing the active ingredient into association with a carrier or one or more other accessory ingredients, and then shaping or packaging the product into the desired single or multiple dosage unit, if necessary or desired.

[0073] As used herein, a "unit dose" is a discrete amount of pharmaceutical composition that contains a predetermined amount of active ingredient. The amount of active ingredient is generally equal to the dosage of active ingredient that would be administered to a subject, or a convenient fraction of such a dosage, such as one-half or one-third of such a dosage. The unit dosage form can be for single daily administration or multiple daily administration (e.g., about 1 to 4 or more times per day). When multiple daily administration is used, the unit dosage form can be the same or different for each dose.

[0074] Although the description of pharmaceutical compositions provided herein is primarily directed to pharmaceutical compositions suitable for ethical administration to humans, those skilled in the art will understand that such compositions are generally suitable for administration to any type of animal. Modifications of pharmaceutical compositions suitable for administration to humans to make the compositions suitable for administration to various animals are well understood, and those skilled in the art of veterinary pharmacology can design and perform such modifications with little, if any, experimentation. Subjects contemplated for administration of the pharmaceutical compositions of the present invention include, but are not limited to, commercially relevant mammals, such as humans and other primates, cows, pigs, horses, sheep, cats, and dogs.

[0075] In one embodiment, the composition of the present invention is formulated using one or more pharma- ceutically acceptable excipients or carriers. In another embodiment, the pharmaceutical composition of the present invention comprises a therapeutically effective amount of at least one composition of the present invention and a pharma- ceutically acceptable carrier. Useful pharma-ceutically acceptable carriers include, but are not limited to, glycerol, water, saline, ethanol, and other pharma- ceutically acceptable salt solutions, such as phosphates and salts of organic acids. Examples of these and other pharma-ceutically acceptable carriers are described in Remington's Pharmaceutical Sciences (1991, Mack Publication Co., New Jersey).

[0076] The carrier may be a solvent or dispersion medium, including, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, sodium chloride, or polyalcohols, such as mannitol and sorbitol, in the composition. Prolonged absorption of the injectable composition can be brought about by including in the composition an agent that delays absorption, for example, aluminum monostearate or gelatin.

[0077] The preparations can be used in admixture with conventional excipients, i.e., pharma- ceutically acceptable organic or inorganic carrier substances suitable for oral, parenteral, intrathecal, nasal, intravenous, subcutaneous, enteral, or any other suitable mode of administration known in the art. Pharmaceutical preparations can be sterilized and, if necessary, can be mixed with auxiliary substances, such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic buffers, coloring substances, flavoring substances and / or aromatic substances, etc. They can also be combined with other active agents, such as other analgesics, if necessary.

[0078] As used herein, "additional ingredients" include, but are not limited to, one or more of the following: excipients; surfactants; dispersing agents; inert diluents; granulating and disintegrating agents; binders; lubricants; sweeteners; flavoring agents; coloring agents; preservatives; biodegradable compositions such as gelatin; aqueous vehicles and solvents; oily vehicles and solvents; suspending agents; dispersing or wetting agents; emulsifying agents, demulcents; buffers; salts; thickening agents; bulking agents; emulsifiers; antioxidants; antibiotics; antifungal agents; stabilizers; and pharmaceutically acceptable polymeric or hydrophobic materials. Other "additional ingredients" that may be included in the pharmaceutical compositions of the present invention are known in the art and are described, for example, in Genaro, ed. (1985, Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA), which is incorporated herein by reference.

[0079] The composition of the present invention may include a preservative at about 0.005% to 2.0% by weight of the total weight of the composition. Preservatives are used to prevent spoilage when exposed to contaminants in the environment. Examples of preservatives useful according to the present invention include, but are not limited to, those selected from the group consisting of benzyl alcohol, sorbic acid, parabens, imidurea, and combinations thereof. An example of a preservative is a combination of about 0.5% to 2.0% benzyl alcohol and 0.05% to 0.5% sorbic acid.

[0080] The composition preferably includes an antioxidant and a chelating agent that inhibits the degradation of the compound. Preferred antioxidants for some compounds are BHT, BHA, alpha-tocopherol, and ascorbic acid in a preferred range of about 0.01% to 0.3% by weight of the total weight of the composition, more preferably BHT in the range of 0.03% to 0.1% by weight. Preferably, the chelating agent is present in an amount of 0.01% to 0.5% by weight of the total weight of the composition. Particularly preferred chelating agents include edetate (disodium edetate) and citric acid in the range of about 0.01% to 0.1% by weight of the total weight of the composition, more preferably in the range of 0.02% to 0.10% by weight. Chelating agents are useful for chelating metal ions in the composition that may adversely affect the shelf life of the formulation. BHT and disodium edetate are particularly preferred antioxidants and chelating agents, respectively, for certain compounds, although other suitable and equivalent antioxidants and chelating agents may be substituted accordingly, as known to those skilled in the art.

[0081] Liquid suspensions can be prepared using conventional methods to achieve suspension of active ingredients in aqueous or oily vehicles. Aqueous vehicles include, for example, water and isotonic saline. Oily vehicles include, for example, almond oil, oily esters, ethyl alcohol, vegetable oils such as arachis oil, olive oil, sesame oil, or coconut oil, fractionated vegetable oils, and mineral oils such as liquid paraffin. Liquid suspensions may further include one or more additional ingredients, including, but not limited to, suspending agents, dispersing or wetting agents, emulsifying agents, demulcents, preservatives, buffers, salts, flavoring agents, coloring agents, and sweetening agents. Oily suspensions may further include a thickening agent. Known suspending agents include, but are not limited to, sorbitol syrup, hydrogenated edible fats and oils, sodium alginate, polyvinylpyrrolidone, gum tragacanth, gum acacia, and cellulose derivatives such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, and the like. Known dispersing or wetting agents include, but are not limited to, naturally occurring phosphatides such as lecithin, condensation products of alkylene oxides with fatty acids, condensation products of long chain aliphatic alcohols, condensation products of partial esters derived from fatty acids with hexitols, or condensation products of partial esters derived from fatty acids with hexitol anhydrides (e.g., polyoxyethylene stearate, heptadecaethyleneoxycetanol, polyoxyethylene sorbitol monooleate, and polyoxyethylene sorbitan monooleate, respectively). Known emulsifying agents include, but are not limited to, lecithin, and acacia. Known preservatives include, but are not limited to, methyl, ethyl, or n-propyl parahydroxybenzoates, ascorbic acid, and sorbic acid. Known sweetening agents include, for example, glycerol, propylene glycol, sorbitol, sucrose, and saccharin. Known thickening agents for oily suspensions include, for example, beeswax, hard paraffin, and cetyl alcohol.

[0082] A liquid solution of an active ingredient in an aqueous or oily solvent can be prepared in substantially the same manner as a liquid suspension, with the main difference being that the active ingredient is dissolved in the solvent rather than suspended. As used herein, an "oily" liquid is one that contains carbon-containing liquid molecules and exhibits less polar properties than water. It is understood that a liquid solution of the pharmaceutical composition of the present invention may contain each of the components described for a liquid suspension, and that the suspending agent does not necessarily aid in dissolving the active ingredient in the solvent. Aqueous solvents include, for example, water, and isotonic saline. Oily solvents include, for example, almond oil, oily esters, ethyl alcohol, vegetable oils such as peanut oil, olive oil, sesame oil, or coconut oil, fractionated vegetable oils, and mineral oils such as liquid paraffin. Powdered and granular formulations of the pharmaceutical preparation of the present invention can be prepared using known methods. Such formulations can be administered directly to a subject, for example, to form tablets, to fill capsules, or to prepare aqueous or oily suspensions or solutions by adding aqueous or oily vehicles thereto. Each of these formulations may further comprise one or more of a dispersing or wetting agent, a suspending agent, and a preservative. Additional excipients, such as bulking agents and sweetening, flavoring, or coloring agents, may also be included in these formulations.

[0083] The pharmaceutical composition of the present invention can also be prepared, packaged, or sold in the form of an oil-in-water emulsion or a water-in-oil emulsion. The oil phase can be a vegetable oil, such as olive oil or arachis oil, a mineral oil, such as liquid paraffin, or a combination thereof. Such compositions can further comprise one or more emulsifiers, such as naturally occurring gums, such as gum acacia or gum tragacanth, naturally occurring phosphatides, such as soybean or lecithin phosphatides, esters or partial esters derived from the combination of fatty acids and hexitol anhydrides, such as sorbitan monooleate, and condensation products of such partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate. These emulsions can also contain additional ingredients, including, for example, sweeteners or flavoring agents.

[0084] Methods for impregnating or coating materials with chemical compositions are known in the art and include, but are not limited to, depositing or bonding the chemical composition to a surface, incorporating the chemical composition into the structure of a material during its synthesis (i.e., for example, with physiologically degradable materials), and absorbing aqueous or oily solutions or suspensions into absorbent materials with or without subsequent drying.

[0085] Administration / Dosage: Dosage schedules can affect what constitutes an effective amount. Therapeutic formulations can be administered to patients before or after the onset of symptoms related to a disease or condition. In addition, several divided doses and staggered doses can be administered daily or sequentially, or the dose can be continuously infused or bolus injection. Furthermore, the dosage of therapeutic formulations can be proportionally increased or decreased as indicated by the exigencies of the therapeutic or prophylactic situation.

[0086] Administration of the compositions of the present invention to a patient, preferably a mammal, more preferably a human, can be carried out using known procedures at dosages and for periods of time effective to treat the patient's disease or condition. The effective amount of the therapeutic compound required to achieve a therapeutic effect can vary depending on factors well known in the medical art, such as: the activity of the particular compound used; the timing of administration; the excretion rate of the compound; the duration of treatment; other drugs, compounds or materials used in combination with the compound; the state of the disease or disorder; the age, sex, weight, condition, general health, and previous medical history of the patient being treated. Dosage regimens can be adjusted to provide the optimal therapeutic response. For example, several divided doses can be administered daily, or the dose can be proportionally reduced as indicated by the exigencies of the therapeutic situation. A non-limiting example of an effective dose range for the therapeutic compounds of the present invention is about 0.01 to 50 mg / kg body weight / day. One of ordinary skill in the art would be able to examine the relevant factors and make a determination regarding the effective amount of the therapeutic compound without undue experimentation.

[0087] The compound may be administered to an animal as frequently as several times a day, or may be administered less frequently, such as once a day, once a week, once every two weeks, once a month, or even less frequently, such as once every few months or even once a year or less. It should be understood that the amount of compound administered per day may be administered every day, every other day, every 2nd day, every 3rd day, every 4th day, or every 5th day, in non-limiting examples. For example, every other day administration may begin with a 5 mg / day dose on Monday, the first subsequent 5 mg / day dose on Wednesday, the second subsequent 5 mg / day dose on Friday, etc. The frequency of administration will be readily apparent to one skilled in the art and will depend on any number of factors, including, but not limited to, the type and severity of the disease being treated, the type and age of the animal.

[0088] The actual dosage level of the active ingredient in the pharmaceutical compositions of the present invention can be varied to obtain an amount of the active ingredient effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration without being harmful to the patient.

[0089] A medical practitioner, e.g., a physician or veterinarian, having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required; for example, the physician or veterinarian can start doses of the compounds of the invention used in the pharmaceutical composition at levels lower than those required to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.

[0090] For ease of administration and uniformity of dosage, it is particularly advantageous to formulate the compound into dosage unit form.As used herein, "dosage unit form" refers to a physically separate unit suitable as a unitary dosage for the patient to be treated: each unit contains a predetermined amount of therapeutic compound calculated to produce a desired therapeutic effect in association with a required pharmaceutical vehicle.The dosage unit form of the present invention is determined by and directly depends on (a) the unique characteristics of the therapeutic compound and the specific therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding / formulating such therapeutic compound for the treatment of cancer in patients.

[0091] In one embodiment, the compositions of the present invention are administered to a patient in a dosage range ranging from 1 to 5 or more times per day. In another embodiment, the compositions of the present invention are administered to a patient in a dosage range including, but not limited to, once every day, every 2 days, every 3 days to once a week, and once every 2 weeks. It will be readily apparent to one of skill in the art that the frequency of administration of the various combination compositions of the present invention will vary from subject to subject depending on many factors including, but not limited to, age, disease or disorder being treated, sex, overall health, and other factors. Thus, the present invention should not be construed as being limited to any particular dosing regimen, and the exact dosage and composition administered to any patient will be determined by the attending physician, taking into account all other factors related to the patient.

[0092] The compound of the present invention to be administered may be in the form of a single dose of about 1 mg to about 7,500 mg, about 20 mg to about 7,000 mg, about 40 mg to about 6,500 mg, about 80 mg to about 6,000 mg, about 100 mg to about 5,500 mg, about 200 mg to about 5,000 mg, about 400 mg to about 4,000 mg, about 800 mg to about 3,000 mg, about 1 mg to about 2,500 mg, about 2 ... The dosage may range from about 100 mg to about 2,000 mg, from about 5 mg to about 1,000 mg, from about 10 mg to about 750 mg, from about 20 mg to about 600 mg, from about 30 mg to about 500 mg, from about 40 mg to about 400 mg, from about 50 mg to about 300 mg, from about 60 mg to about 250 mg, from about 70 mg to about 200 mg, from about 80 mg to about 150 mg, and all whole and partial increments therebetween.

[0093] In some embodiments, the dosage of the compound of the invention is from about 0.5 mg to about 5000 mg. In some embodiments, the dosage of the compound of the invention used in the compositions described herein is less than about 5000 mg, or less than about 4000 mg, or less than about 3000 mg, or less than about 2000 mg, or less than about 1,000 mg, or less than about 800 mg, or less than about 600 mg, or less than about 500 mg, or less than about 200 mg, or less than about 50 mg. Similarly, in some embodiments, the dose of a second compound described herein is less than about 1,000 mg, or less than about 800 mg, or less than about 600 mg, or less than about 500 mg, or less than about 400 mg, or less than about 300 mg, or less than about 200 mg, or less than about 100 mg, or less than about 50 mg, or less than about 40 mg, or less than about 30 mg, or less than about 25 mg, or less than about 20 mg, or less than about 15 mg, or less than about 10 mg, or less than about 5 mg, or less than about 2 mg, or less than about 1 mg, or less than about 0.5 mg, and all whole and partial increments therebetween.

[0094] In one embodiment, the invention relates to a packaged pharmaceutical composition comprising a container housing a therapeutically effective amount of a compound of the invention, alone or in combination with a second pharmaceutical agent, and instructions for using the compound to treat, prevent, or alleviate one or more symptoms of a disease or disorder in a patient.

[0095] The term "container" includes any receptacle for containing a pharmaceutical composition. For example, in one embodiment, the container is a package containing the pharmaceutical composition. In other embodiments, the container is not a package containing the pharmaceutical composition, i.e., the container is a receptacle such as a box or vial that contains the packaged or unpackaged pharmaceutical composition, as well as instructions on the use of the pharmaceutical composition. Furthermore, packaging techniques are well known in the art. It should be understood that instructions on the use of the pharmaceutical composition may be included on the package containing the pharmaceutical composition, such that the instructions enhance the functional relationship with the packaged product. However, it should be understood that the instructions may include information regarding the ability of the compound to perform its intended function, for example, to treat, prevent, or alleviate a disease or disorder in a patient.

[0096] Route of Administration: Routes of administration of any of the compositions of the invention include inhalation, oral, nasal, rectal, parenteral, sublingual, transdermal, transmucosal (e.g., sublingual, lingual, buccal, urethral, ​​vaginal (e.g., vaginal and perivaginal), nasal, and rectal), intravesical, intrapulmonary, intraduodenal, intragastric, intrathecal, subcutaneous, intramuscular, intradermal, intracranial, intraarterial, intravenous, intrabronchial, inhalation, and topical administration.

[0097] Suitable compositions and dosage forms include, for example, tablets, capsules, caplets, pills, gelcaps, troches, dispersions, suspensions, solutions, syrups, granules, beads, transdermal patches, gels, powders, pellets, magmas, lozenges, creams, pastes, ointments, lotions, discs, suppositories, liquid sprays for nasal or oral administration, dry powder or aerosol formulations for inhalation, compositions and formulations for intravesical administration, and the like. It is understood that the formulations and compositions that would be useful in the present invention are not limited to the specific formulations and compositions described herein.

[0098] Oral route For oral application, tablets, dragees, liquids, drops, suppositories, or capsules, caplets and gelcaps are particularly suitable. Other formulations suitable for oral administration include, but are not limited to, powdered or granular formulations, aqueous or oily suspensions, aqueous or oily solutions, pastes, gels, toothpastes, mouthwashes, coatings, oral rinses, or emulsions. Compositions intended for oral use can be prepared according to any method known in the art, and such compositions may contain one or more agents selected from the group consisting of inert, non-toxic pharmaceutical excipients suitable for the manufacture of tablets. Such excipients include inert diluents such as lactose, granulating and disintegrating agents such as cornstarch, binding agents such as starch; and lubricants such as magnesium stearate.

[0099] The tablet may be uncoated or may be coated using known methods to achieve delayed disintegration in the subject's gastrointestinal tract, thereby providing sustained release and absorption of active ingredients.For example, the tablet may be coated using materials such as glyceryl monostearate or glyceryl distearate.For further example, the tablet may be coated using the methods described in U.S. Patent Nos. 4,256,108, 4,160,452, and 4,265,874 to form osmotically controlled release tablets.The tablet may further comprise a sweetener, a flavoring agent, a coloring agent, a preservative, or some combination thereof to provide a pharmacopoeial and palatable preparation.

[0100] For oral administration, the compounds of the present invention may be in the form of tablets or capsules prepared by conventional means using pharma- ceutically acceptable excipients, such as binders, fillers, lubricants, disintegrants, or wetting agents. If necessary, tablets may be coated using appropriate methods and coating materials, such as OPADRY™ film coating systems available from Colorcon, West Point, Pa. (e.g., OPADRY™ OY Type, OYC Type, Organic Enteric OY-P Type, Aqueous Enteric OY-A Type, OY-PM Type, and OPADRY™ White, 32K18400).

[0101] Liquid preparations for oral administration can be in the form of solution, syrup or suspension.Liquid preparations can be prepared by conventional means using pharma- ceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, methylcellulose or hydrogenated edible fats and oils), emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters or ethyl alcohol); and preservatives (e.g., methyl or propyl parahydroxybenzoate or sorbic acid).The liquid formulations of the pharmaceutical compositions of the present invention suitable for oral administration can be prepared, packaged, and sold in liquid form or in the form of a dry product that is intended to be reconstituted with water or another suitable vehicle before use.

[0102] Parenteral Administration As used herein, "parenteral administration" of a pharmaceutical composition includes any administration route characterized by physically creating a hole in the tissue of a subject and administering the pharmaceutical composition through the hole in the tissue. Thus, parenteral administration includes, but is not limited to, administration of a pharmaceutical composition by injection of the composition, application of the composition through a surgical incision, application of the composition through a non-surgical wound that penetrates the tissue, and the like. In particular, parenteral administration is intended to include, but is not limited to, intracranial, subcutaneous, intravenous, intraperitoneal, intramuscular, intraspinal, intrasternal, intrathecal, brainstem injection, and kidney dialysis infusion techniques.

[0103] A formulation of a pharmaceutical composition suitable for parenteral administration comprises the active ingredient combined with a pharma- ceutically acceptable carrier, such as sterile water or sterile isotonic saline. Such formulations may be prepared, packaged, or sold in a form suitable for bolus or continuous administration. Injectable formulations may be prepared, packaged, or sold in unit dosage form, for example in ampoules, or in multi-dose containers containing a preservative. Formulations for parenteral administration include, but are not limited to, suspensions, solutions, emulsions in oily or aqueous vehicles, pastes, and implantable sustained-release or biodegradable formulations. Such formulations may further comprise one or more additional components, including, but not limited to, suspending agents, stabilizing agents, or dispersing agents. In one embodiment of a formulation for parenteral administration, the active ingredient is provided in a dry (i.e., powdered or granular) form for reconstitution with a suitable vehicle (e.g., sterile pyrogen-free water) prior to parenteral administration of the reconstituted composition.

[0104] The pharmaceutical composition may be prepared, packaged, or sold in the form of a sterile injectable aqueous or oily suspension or solution. The suspension or solution may be formulated according to known techniques and may contain, in addition to the active ingredient, additional ingredients such as dispersing agents, wetting agents, or suspending agents described herein. Such sterile injectable preparations may be prepared using, for example, a non-toxic parenterally acceptable diluent or solvent, such as water or 1,3-butanediol. Other acceptable diluents and solvents include, but are not limited to, Ringer's solution, isotonic sodium chloride solution, and fixed oils such as synthetic mono- or diglycerides. Other parenterally administrable formulations that are useful include those that contain the active ingredient in microcrystalline form, in a liposomal preparation, or as a component of a biodegradable polymer system. Compositions for sustained release or implantation may include pharma-ceutically acceptable polymers or hydrophobic materials, such as emulsions, ion exchange resins, sparingly soluble polymers, or sparingly soluble salts.

[0105] Further dosage forms Additional dosage forms of the present invention include those described in U.S. Patent Nos. 6,340,475, 6,488,962, 6,451,808, 5,972,389, 5,582,837, and 5,007,790. Additional dosage forms of the present invention also include those described in U.S. Patent Application Nos. 2003 / 0147952, 2003 / 0104062, 2003 / 0104053, 2003 / 0044466, 2003 / 0039688, and 2002 / 0051820. Additional dosage forms of the present invention also include those described in PCT Application Nos. WO03 / 35041, WO03 / 35040, WO03 / 35029, WO03 / 35177, WO03 / 35039, WO02 / 96404, WO02 / 32416, WO01 / 97783, WO01 / 56544, WO01 / 32217, WO98 / 55107, WO98 / 11879, WO97 / 47285, WO93 / 18755, and WO90 / 11757.

[0106] Sustained Release Formulations and Drug Delivery Systems The sustained or extended release formulation of the pharmaceutical composition of the present invention can be prepared using conventional technology.In some cases, the dosage form used can be provided as a slow or extended release of one or more active ingredients therein, for example, by using hydropropylmethylcellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multi-layer coatings, microparticles, liposomes, or microspheres, or combinations thereof, to provide different ratios of desired release profiles.Any suitable sustained release formulation known to those skilled in the art, including those described herein, can be easily selected for use with the pharmaceutical composition of the present invention.Therefore, the present invention includes single unit dosage forms suitable for oral administration, such as tablets, capsules, gel caps, and caplets adapted for sustained release.

[0107] Most sustained release pharmaceutical products have a common goal of improving drug therapy over that achieved by their non-controlled counterparts. Ideally, the use of an optimally designed sustained release formulation in pharmaceutical therapy will be characterized by the use of a minimum amount of drug substance to cure or control a condition in a minimum amount of time.

[0108] Advantages of sustained release formulations include extended drug activity, reduced dosing frequency, and improved patient compliance. Additionally, sustained release formulations can be used to affect the time of onset of action or other characteristics, such as blood levels of the drug, and therefore can affect the occurrence of side effects.

[0109] Most sustained release formulations are designed to initially release an amount of drug that rapidly produces the desired therapeutic effect, and then gradually and continuously release other amounts of drug to maintain this level of therapeutic effect over an extended period of time. In order to maintain this constant level of drug in the body, the drug must be released from the dosage form at a rate that will replace the amount of drug being metabolized and excreted from the body.

[0110] The sustained release of active ingredient can be stimulated by various inducers, such as pH, temperature, enzymes, water, or other physiological conditions or compounds. The term "sustained release component" in the context of the present invention is defined herein as a compound or compounds, including but not limited to polymers, polymer matrices, gels, permeable membranes, liposomes, or microspheres, or combinations thereof, that promotes the sustained release of active ingredient.

[0111] In certain embodiments, the formulations of the present invention can be, but are not limited to, short term, fast release, and sustained release, including extended release, delayed release, and pulsed release formulations.

[0112] The term sustained release is used in its conventional sense to refer to a drug formulation that gradually releases drug over an extended period of time, which may, but does not necessarily, result in substantially constant blood levels of drug over an extended period of time, which may extend to a month or more and should result in a longer release than the same amount of drug administered in bolus form.

[0113] For sustained release, compound can be formulated with suitable polymer or hydrophobic material that provides compound with sustained release properties.Therefore, compound for using the method of the present invention can be administered, for example, in the form of microparticles by injection, or in the form of wafer or disk by implantation.In a preferred embodiment of the present invention, compound of the present invention is administered to patient by using sustained release formulation, alone or in combination with another pharmaceutical agent.

[0114] The term delayed release is used herein in its conventional sense to refer to a drug formulation that initially releases drug after some delay following drug administration, which may, but does not necessarily, include a delay of from about 10 minutes up to about 12 hours.

[0115] The term pulsatile release is used herein in its conventional sense to refer to a drug formulation that releases drug in such a manner as to produce a pulsatile plasma profile of the drug following drug administration.

[0116] The term immediate release is used in its conventional sense to refer to a formulation that releases drug immediately after drug administration.

[0117] As used herein, short-term refers to any period of time up to and including about 8 hours, about 7 hours, about 6 hours, about 5 hours, about 4 hours, about 3 hours, about 2 hours, about 1 hour, about 40 minutes, about 20 minutes, or about 10 minutes after drug administration, and any or whole or partial increments thereof.

[0118] As used herein, rapid elimination refers to any period up to and including about 8 hours, about 7 hours, about 6 hours, about 5 hours, about 4 hours, about 3 hours, about 2 hours, about 1 hour, about 40 minutes, about 20 minutes, or about 10 minutes after drug administration, and any whole or partial increments therein.

[0119] Those skilled in the art will recognize or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific procedures, embodiments, claims, and examples described herein. Such equivalents are considered to be within the scope of the present invention and are encompassed by the claims appended hereto. For example, variations in reaction conditions, including but not limited to reaction times, reaction sizes / volumes, and solvents, experimental reagents such as catalysts, pressure, atmospheric conditions, e.g., nitrogen atmosphere, and reducing / oxidizing agents, using art-recognized substitutions and no more than routine experimentation, are understood to be within the scope of this application.

[0120] definition To aid in understanding the detailed description of the compositions and methods according to the present disclosure, some explicit definitions are provided to facilitate clear disclosure of the various aspects of the present disclosure. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0121] As used herein, "expression" refers to the process by which a polynucleotide is transcribed from a DNA template (such as into an mRNA or other RNA transcript) and / or the process by which the transcribed mRNA is subsequently translated into a peptide, polypeptide, or protein. The transcript and the encoded polypeptide can be collectively referred to as a "gene product." If the polynucleotide is derived from genomic DNA, expression can include splicing of the mRNA in a eukaryotic cell.

[0122] The term "gene" refers to a nucleic acid (e.g., DNA or RNA) sequence that comprises the coding sequence necessary for the production of an RNA or a polypeptide or its precursor (e.g., proinsulin). A functional polypeptide can be encoded by a full-length coding sequence or any portion of a coding sequence, so long as the desired activity or functional property of the polypeptide (e.g., enzymatic activity, ligand binding, signal transduction, etc.) is retained. The term "portion" when used in reference to a gene refers to a fragment of that gene. The size of the fragment can vary from a few nucleotides to the entire gene sequence minus one nucleotide. Thus, "nucleotides comprising at least a portion of a gene" may include a fragment of a gene or the entire gene.

[0123] The term "gene" also encompasses the coding region of a structural gene and includes sequences located adjacent to the coding region at both the 5' and 3' ends at a distance of about 1 kb on either side such that the gene corresponds to the length of the full-length mRNA. Sequences located 5' of the coding region and present on the mRNA are referred to as 5' non-translated sequences. Sequences located 3' or downstream of the coding region and present on the mRNA are referred to as 3' non-translated sequences. The term "gene" encompasses both cDNA and genomic forms of a gene. Genomic forms or clones of a gene contain coding regions interrupted with non-coding sequences referred to as "introns" or "intervening regions" or "intervening sequences". Introns are segments of a gene that are transcribed into nuclear RNA (hnRNA) and may contain regulatory elements such as enhancers. Introns are removed or "spliced ​​out" from the nuclear or primary transcript and therefore are absent from the messenger RNA (mRNA) transcript. The mRNA functions during translation to specify the sequence or order of amino acids in a nascent polypeptide.

[0124] "Gene transfer" and "gene delivery" refer to a method or system for reliably inserting specific nucleic acid sequences into a target cell.

[0125] The term "recombinant" when made with respect to a nucleic acid molecule refers to a nucleic acid molecule that is comprised of segments of nucleic acid joined together by means of molecular biological techniques. The term "recombinant" when made with respect to a protein or polypeptide refers to a protein molecule that is expressed using a recombinant nucleic acid molecule.

[0126] The term "operably linked" refers to a functional link between a regulatory sequence and a heterologous nucleic acid sequence that results in the expression of the latter. For example, a first nucleic acid sequence is operably linked to a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For example, a promoter is operably linked to a coding sequence when the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences are contiguous and, where necessary to join two protein coding regions, are in the same reading frame.

[0127] As used herein, the term "in vitro" refers to events that take place not within a multicellular organism but in an artificial environment, e.g., in a test tube or reaction vessel, in cell culture, etc.

[0128] As used herein, the term "in vivo" refers to events that occur within a multicellular organism, such as a non-human animal.

[0129] As used herein, "treatment" or "treating" or "alleviating" or "ameliorating" are used interchangeably. These terms refer to an approach to obtain beneficial or desired results, including but not limited to therapeutic benefit and / or preventive benefit. Therapeutic benefit refers to any treatment-related improvement in or effect on one or more diseases, conditions, or symptoms being treated. In the case of preventive benefit, the composition can be administered to a subject at risk of developing a particular disease, condition, or symptom, or a subject reporting one or more physiological symptoms of a disease, even if the disease, condition, or symptom has not yet appeared.

[0130] The terms "prevent," "preventing," "prevention," "prophylactic treatment," and the like refer to reducing the likelihood of developing a disorder or condition in a subject who does not have the disorder or condition, but is at risk or susceptible to developing the disorder or condition.

[0131] The term "disease" as used herein is intended to be generally synonymous with, and is used interchangeably with, the terms "disorder" and "condition" (as in medical condition), in that all reflect an abnormal condition that prevents one of the human or animal body parts from functioning normally, is typically manifested by distinguishing signs and symptoms, and reduces the duration or quality of life of a human or animal.

[0132] The terms "reduction", "decreased", "reduction", "reduce", or "inhibit" are all used herein generally to mean a statistically significant amount of reduction. However, to avoid any doubt, "decreased", "reduction" or "reduce" or "inhibit" means a reduction of at least 10% compared to a reference level, for example, a reduction of at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90% reduction, or any reduction up to and including 100% (absence of level compared to a reference sample), or any reduction between 10 and 100% compared to a reference level.

[0133] As used herein, the term "modulate" is meant to refer to any change in a biological state, ie, an increase, a decrease, and the like.

[0134] The terms "increased", "increase" or "enhancement" or "activation" are all used herein to generally mean a statically significant amount of increase. For the avoidance of doubt, the terms "increased", "increase" or "enhancement" or "activation" mean an increase of at least 10% compared to a reference level, for example, at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90%, or an increase of less than or including 100%, or any increase of 10-100% compared to a reference level, or at least about 2-fold, or at least about 3-fold, or at least about 4-fold, or at least about 5-fold, or at least about 10-fold, or any increase of 2-fold to 10-fold or more compared to a reference level.

[0135] The term "effective amount", "effective dose", or "effective dosage" is defined as an amount sufficient to achieve or at least partially achieve a desired effect. A "therapeutically effective amount" or "therapeutically effective dosage" of a drug or therapeutic agent is any amount of the drug that, when used alone or in combination with another therapeutic agent, promotes regression of a disease as evidenced by a decrease in the severity of disease symptoms, an increase in the frequency and duration of disease symptom-free periods, or prevention of functional impairment or disability due to disease affliction. A "prophylactically effective amount" or "prophylactically effective dosage" of a drug is an amount of the drug that inhibits the onset or recurrence of a disease when administered alone or in combination with another therapeutic agent to a subject at risk of developing a disease or at risk of recurring a disease. The ability of a therapeutic or prophylactic agent to promote regression of a disease or inhibit the onset or recurrence of a disease can be evaluated using a variety of methods known to the skilled practitioner, for example, by assaying the activity of the agent in human subjects during clinical trials, in animal model systems predictive of efficacy in humans, or in in vitro assays.

[0136] Doses are often expressed in relation to body weight. Thus, a dose expressed as [g, mg, or other unit] / kg (or g, mg, etc.) usually refers to [g, mg, or other unit] "per kg (or g, mg, etc.) body weight", even if the term "body weight" is not explicitly mentioned.

[0137] The term "agent" is used herein to denote a chemical compound, a mixture of compounds, a biological macromolecule (such as a nucleic acid, an antibody, a protein or a portion thereof, e.g., a peptide, etc.), or an extract made from biological material such as a bacterial, plant, fungus, or animal (especially mammalian) cell or tissue. The activity of such agents may qualify them as "therapeutic agents," which are biologically, physiologically, or pharmacologically active substances (or substances) that act locally or systemically in a subject.

[0138] The terms "therapeutic agent," "therapeutic potential agent," or "therapeutic agent" are used interchangeably and refer to a molecule or compound that confers some beneficial effect when administered to a subject. Beneficial effects include enabling a diagnostic determination; ameliorating a disease, symptom, disorder, or pathological condition; reducing or preventing the onset of a disease, symptom, disorder, or condition; and counteracting a disease, symptom, disorder, or pathological condition altogether.

[0139] As used herein, "combination" therapy is meant to include administration of two or more therapeutic agents in a coordinated manner, unless otherwise clear from the context, including but not limited to simultaneous administration. Specifically, combination therapy includes both simultaneous administration (e.g., administration of a combination agent or simultaneous administration of separate therapeutic compositions) and sequential or sequential administration, provided that administration of one therapeutic agent is in some way conditioned on administration of another therapeutic agent. For example, one therapeutic agent may be administered only after another therapeutic agent has been administered and allowed to act for a certain period of time. See, for example, Kohrt et al. (2011) Blood 117:2423.

[0140] "Sample", "test sample", and "patient sample" may be used interchangeably herein. A sample may be a sample of serum, urine plasma, amniotic fluid, cerebrospinal fluid, cells (e.g., antibody-producing cells), or tissue. Such samples may be used directly as obtained from a patient, or may be pretreated by filtration, distillation, extraction, concentration, centrifugation, inactivation of interfering components, addition of reagents, etc., to alter the characteristics of the sample in some manner as discussed herein or otherwise known in the art. As used herein, the terms "sample" and "biological sample" generally refer to biological material that is tested for and / or suspected of containing an analyte of interest, such as an antibody. A sample may be any tissue sample from a subject. A sample may contain proteins from a subject.

[0141] "Homology" as used herein refers to the subunit sequence identity between two polymer molecules, e.g., between two nucleic acid molecules, such as two DNA molecules or two RNA molecules, or between two polypeptide molecules. If a subunit position in both of the two molecules is occupied by the same monomeric subunit, e.g., if a position in each of the two DNA molecules is occupied by adenine, then they are homologous at that position. The homology between two sequences is a direct function of the number of matching or homologous positions, e.g., if half of the positions in two sequences (e.g., 5 positions in a polymer 10 subunits long) are homologous, then the two sequences are 50% homologous. If 90% of the positions (e.g., 9 out of 10) are matched or homologous, then the two sequences are 90% homologous. As an example, the DNA sequences 5'-ATTGCC-3' and 5'-TATGGC-3' share 50% homology.

[0142] An "inducible" promoter is a nucleotide sequence that, when operably linked to a polynucleotide encoding or specifying a gene product, causes that gene product to be produced in a cell substantially only if an inducer corresponding to that promoter is present in the cell.

[0143] The terms "inhibit" and "antagonize" as used herein refer to the measurable reduction or complete prevention of the expression, stability, function or activity of a molecule, reaction, interaction, gene, mRNA, and / or protein. Inhibitors are compounds, e.g., antagonists, that bind to, for example, proteins, genes, and mRNAs and partially or completely block stimulation, reduce, prevent, delay activation, inactivate, desensitize, or downregulate stability, expression, function, and activity.

[0144] "Instructional material," as the term is used herein, includes publications, records, drawings, or any other medium of expression that can be used to communicate the utility of any composition and / or compound of the present invention in the kit. The kit's instructional material can be, for example, affixed to a container containing any composition of the present invention or shipped together with a container containing any composition. Alternatively, the instructional material can be shipped separately from the container with the intention that the recipient will use the instructional material and any composition in a coordinated manner. Delivery of the instructional material can be, for example, by physical delivery of a publication or other medium of expression that communicates the utility of the kit, or can alternatively be accomplished by electronic transmission by computer, such as, for example, email, or download from a website.

[0145] "Isolated" means altered or removed from the natural state. For example, a nucleic acid or peptide naturally present in a living animal is not "isolated," but the same nucleic acid or peptide partially or completely separated from the coexisting materials of its natural state is "isolated." An isolated nucleic acid or protein may exist in a substantially purified form, or may exist in a non-native environment, such as, for example, a host cell.

[0146] "Isolated nucleic acid" refers to a nucleic acid segment or fragment separated from sequences adjacent to it in its naturally occurring state, i.e., a DNA fragment removed from sequences that normally flank the fragment, i.e., sequences adjacent to the fragment in the genome in which it naturally occurs. The term also applies to nucleic acids that have been substantially purified from other components that naturally accompany the nucleic acid, i.e., the RNA or DNA or proteins that naturally accompany it in a cell. Thus, the term includes recombinant DNA that is incorporated into, for example, a vector, an autonomously replicating plasmid or virus, or the genomic DNA of a prokaryote or eukaryote, or exists as a separate molecule independent of other sequences (i.e., as a cDNA or genomic or cDNA fragment generated by PCR or restriction enzyme digestion). It also includes recombinant DNA that is part of a hybrid gene that encodes additional polypeptide sequences.

[0147] Unless otherwise specified, a "nucleotide sequence encoding an amino acid sequence" includes all nucleotide sequences that are degenerate versions of each other and that encode the same amino acid sequence. The phrase nucleotide sequence encoding a protein or RNA may include introns to the extent that a nucleotide sequence encoding a protein may contain introns in some versions.

[0148] "Parenteral" administration of a composition includes, for example, subcutaneous (sc), intravenous (iv), intramuscular (im), or intrasternal injection, intrathecal, or infusion techniques.

[0149] As used herein, the term "pharmaceutical composition" refers to a mixture of at least one compound useful within the present invention with other chemical components, such as carriers, stabilizers, diluents, dispersants, suspending agents, thickeners, and / or excipients, that facilitate administration of the compound to an organism.

[0150] Multiple techniques exist in the art for administering a compound, including but not limited to intravenous, oral, aerosol, parenteral, ophthalmic, pulmonary and topical administration.

[0151] As used herein, the term "pharmaceutical acceptable" refers to a material, such as a carrier or diluent, that does not abrogate the biological activity or properties of the composition and is relatively non-toxic, i.e., the material may be administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.

[0152] The phrase "pharmaceutically acceptable carrier" includes pharmaceutically acceptable salts, pharmaceutically acceptable materials, compositions, or carriers, such as liquid or solid fillers, diluents, excipients, solvents, or encapsulating materials, that are involved in carrying or transporting the compound(s) of the present invention in or to a subject so that it can perform its intended function. Typically, such compounds are carried or transported from one organ or part of the body to another. Each salt or carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not harmful to the subject. Some examples of materials that can serve as pharma-ceutically acceptable carriers include: sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository wax; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; and glycols such as propylene glycol. ;polyols such as glycerin, sorbitol, mannitol, and polyethylene glycol;esters such as ethyl oleate and ethyl laurate;agar;buffers such as magnesium hydroxide and aluminum hydroxide;alginic acid;pyrogen-free water;isotonic saline;Ringer's solution;ethyl alcohol;phosphate buffer;diluents;granulating agents;lubricants;binding agents;disintegrating agents;humectants;emulsifying agents;coloring agents;releasing agents;coating agents;sweetening agents;flavoring agents;preservatives;antioxidants;plasticizers;gelling agents;thickening agents;hardeners;setting agents;suspending agents;surfactants;humectants;carriers;stabilizers;and other non-toxic compatible substances used in pharmaceutical formulations, or any combination thereof.As used herein, "pharmaceutically acceptable carrier" also includes any and all coatings, antibacterial and antifungal agents, and absorption delaying agents, etc., that are compatible with the activity of the compound and are physiologically acceptable to the subject.Supplementary active compounds may also be incorporated into the composition.

[0153] As used herein, the phrase "pharmaceutically acceptable salts" refers to salts of the administered compound prepared from pharmaceutically acceptable non-toxic acids, including inorganic acids, organic acids, solvates, hydrates, or clathrates thereof.

[0154] "Polypeptide" refers to a polymer composed of amino acid residues, related naturally occurring structural variants, and synthetic, non-naturally occurring analogs thereof linked via peptide bonds. Synthetic polypeptides can be synthesized, for example, using automated polypeptide synthesizers. The term "protein" typically refers to large polypeptides. The term "peptide" typically refers to short polypeptides.

[0155] Conventional notation is used herein to depict polypeptide sequences, with the left end of the polypeptide sequence being the amino terminus and the right end of the polypeptide sequence being the carboxyl terminus. As used herein, a "peptide mimetic" is a compound that contains non-peptide structural elements that can mimic the biological action of a parent peptide. A peptidomimetic may or may not contain peptide bonds.

[0156] The term "promoter" as used herein is defined as a DNA sequence that is recognized by the synthetic machinery of a cell, or introduced synthetic machinery, and is required to initiate the specific transcription of a polynucleotide sequence.

[0157] As used herein, the term "promoter / regulatory sequence" refers to a nucleic acid sequence required for expression of a gene product operably linked to the promoter / regulatory sequence. In some cases, this sequence may be a core promoter sequence, and in other cases, this sequence may also include enhancer sequences and other regulatory elements required for expression of the gene product. The promoter / regulatory sequence may, for example, be one that expresses the gene product in a tissue-specific manner.

[0158] The term "recombinant polypeptide" as used herein is defined as a polypeptide produced by using recombinant DNA methods. The term "recombinant DNA" as used herein is defined as DNA produced by combining pieces of DNA from different sources.

[0159] The term "RNA" as used herein is defined as ribonucleic acid. The term "specifically binds" or "specifically binds" as used herein means that a first molecule (e.g., an antibody) binds preferentially to a second molecule (e.g., a particular antigenic epitope), but not necessarily exclusively to the second molecule.

[0160] As used herein, a "subject" refers to a human or non-human mammal. Non-human mammals include livestock and pets, such as, for example, sheep, cows, pigs, dogs, cats, and mice. In certain embodiments, the subject is a human. A "tissue-specific" promoter is a nucleotide sequence that, when operably linked to a polynucleotide encoding or specified by a gene, causes the gene product to be produced in a cell substantially only if the cell is a cell of the tissue type corresponding to the promoter.

[0161] The terms "transfected" or "transformed" or "transduced" as used herein refer to the process by which exogenous nucleic acid is transferred or introduced into a host cell. A "transfected" or "transformed" or "transduced" cell has been transfected, transformed or transduced with exogenous nucleic acid. The cell includes the primary subject cell and its progeny.

[0162] The phrase "under transcriptional control" or "operably linked" as used herein means that the promoter is in the correct position and orientation relative to the polynucleotide to control the initiation of transcription by RNA polymerase and the expression of the polynucleotide. "Variant" as the term is used herein is a nucleic acid sequence or peptide sequence that differs in sequence from the reference nucleic acid sequence or peptide sequence, respectively, but retains the essential properties of the reference molecule. The change in the sequence of the nucleic acid variant may not change the amino acid sequence of the peptide encoded by the reference nucleic acid, or may result in amino acid substitution, addition, deletion, fusion, and truncation. The change in the sequence of the peptide variant is typically limited or conservative, so that the sequences of the reference peptide and the variant are generally very similar and in many regions are identical.

[0163] Variants and reference peptides may differ in amino acid sequence by one or more substitutions, additions, or deletions in any combination. Nucleic acid or peptide variants may be naturally occurring variants such as allelic variants, or may be variants that are not known to occur naturally. Non-naturally occurring nucleic acid and peptide variants can be made by mutagenesis techniques or direct synthesis.

[0164] A "vector" is a composition of matter that contains an isolated nucleic acid and can be used to deliver the isolated nucleic acid to the inside of a cell. Numerous vectors are known in the art, including but not limited to linear polynucleotides, polynucleotides associated with ionic or amphiphilic compounds, plasmids, and viruses. Thus, the term "vector" includes autonomously replicating plasmids or viruses. The term should also be construed to include non-plasmid and non-viral compounds that facilitate the transfer of nucleic acid into cells, such as polylysine compounds, liposomes, etc. Examples of viral vectors include, but are not limited to, adenoviral vectors, adeno-associated viral vectors, retroviral vectors, etc.

[0165] As used herein, the term "virus" is defined as a particle consisting of nucleic acid (RNA or DNA) enclosed in a protein coat, with or without an outer lipid envelope, that is capable of transfecting cells with its nucleic acid.

[0166] Throughout this disclosure, various aspects of the invention can be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Thus, the description of a range should be considered to specifically disclose all possible subranges as well as individual numerical values ​​within that range. For example, the description of a range such as 1-6 should be considered to specifically disclose subranges such as 1-3, 1-4, 1-5, 2-4, 2-6, 3-6, etc. as well as individual numerical values ​​within that range, such as 1, 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the breadth of the range.

[0167] It should be noted that as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0168] The terms "including," "comprising," "containing," or "having" and variations thereof are meant to encompass the items listed thereafter, and equivalents thereof, as well as additional subject matter, unless expressly stated otherwise.

[0169] The phrases "in one embodiment," "in various embodiments," "in some embodiments," and the like are used repeatedly. Such phrases do not necessarily refer to the same embodiment, but may do so unless context dictates otherwise.

[0170] The term "and / or" or " / " means any one of the items, any combination of the items, or all of the items with which this term is associated.

[0171] The word "substantially" does not exclude "completely", e.g. a composition that is "substantially free" of Y may be completely free of Y. If desired, the word "substantially" may be omitted from the definition of the invention.

[0172] As used herein, the term "approximately" or "about" refers to a value similar to the stated reference value when applied to one or more values. In some embodiments, the term "approximately" or "about" refers to a range of values ​​that are within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less of the stated reference value, unless otherwise stated or clear from the context (except when such number exceeds 100% of possible values). Unless otherwise indicated herein, the term "about" is intended to include values ​​close to the stated range, e.g., weight percentages, that are equivalent in terms of the function of the individual components, compositions, or embodiments.

[0173] It is to be understood that whenever values ​​and ranges are provided herein, all values ​​and ranges subsumed within those values ​​and ranges are meant to be encompassed within the scope of the present invention. Moreover, all values ​​that fall within these ranges, as well as the upper or lower limits of a range of values, are also contemplated by the application.

[0174] As used herein, the term "each," when used in reference to a collection of items, is intended to identify each individual item in the collection, but does not necessarily refer to every item in the collection. Exceptions may occur where explicit disclosure or context clearly dictates otherwise.

[0175] The use of any and all examples provided herein, or exemplary language (e.g., "etc.") is intended merely to clarify the invention and does not impose limitations on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.

[0176] All methods described herein can be performed in any suitable order unless otherwise indicated herein or clearly contradicted by context. For any of the methods provided, the steps of the method can be performed simultaneously or sequentially. When the steps of the method are performed sequentially, the steps can be performed in any order unless otherwise indicated.

[0177] Where a method includes a combination of steps, any and all combinations or subcombinations of the steps are included within the scope of the disclosure, unless otherwise stated herein.

[0178] Each publication, patent application, patent, and other reference cited herein is incorporated by reference in its entirety to the extent that it does not conflict with this disclosure. Publications disclosed herein are provided solely for their disclosure prior to the filing date of the present invention. Nothing herein should be construed as an admission that the present invention is not entitled to antedate such publications by virtue of prior invention. Additionally, publication dates provided may differ from the actual publication dates, which may need to be independently confirmed.

[0179] It should be understood that the examples and embodiments described herein are for illustrative purposes only, and that various modifications or changes in light thereof will be suggested to those skilled in the art and are within the spirit and scope of this application and the appended claims. EXAMPLES

[0180] Example 1 All starting materials were obtained from commercial suppliers and used without purification unless otherwise stated. As described in this paper, patient-derived induced pluripotent stem cells (iPSCs) were obtained from an NIH-funded biorepository (www.nimhgenetics.org / available_data / ipsc / ). Both normal healthy cells and cells from individuals carrying a mutation in SOD1(N139K) and diagnosed with familial ALS were used. A differentiation protocol has been established that results in the culture of motor neurons after 40 days of treatment with a defined regimen of growth factors and specialized media (Figure 1). Therapeutic (ASPA) and control (GFP) genes were packaged into AAV vectors and initial cohorts of cells were treated to evaluate their impact on mitochondrial function. Mitochondria isolated from SOD1 mutant motor neurons were shown to have a lower ATP synthesis rate compared to wild-type cells, but transduction of these mutant cells with AAV-ASPA significantly restored mitochondrial ATP synthesis rate compared to AAV-GFP controls, as assessed by a luminescence-based in situ assay (Figure 2).

[0181] Example 2 Analysis of the stimulation of ATP synthesis by ASPA-derived free aspartate in mitochondria isolated from the spinal cord of 16-week-old SOD G93A mice. Mitochondria were isolated from 16-week-old SOD G93A whole spinal cords using mechanical homogenization and differential centrifugation. Mitochondria were kept on ice until use in the assay. The rate of ATP synthesis was analyzed in 30 μg of isolated mitochondria using a commercially available luminescence-based kit. A reaction mixture containing 1.0 mM malate, 1.0 mM glutamate, 10 mM NADH, and 0.2 mM ADP was prepared in a solution containing luciferase and luciferin, and 30 μg of mitochondria was added. Addition of 2 U / ml aspartate aminotransferase and 3 U / ml malate dehydrogenase drives MAS and initiates ATP synthesis. In this example, free aspartate was used in place of the reaction product generated by incubating lysates from cells overexpressing either wild-type ASPA or non-functional mutant ASPA with 5 mM NAA, following the scheme in Figure 8. Addition of wild-type ASPA reaction products to SOD spinal cord mitochondria significantly increased the rate of ATP synthesis as measured by luminescence over 3 min, but addition of the nonfunctional E285A ASPA mutant reaction product did not (Figure 9). The aspartate content of these reaction products was assessed by HPLC (Table 1), indicating a >800-fold increase in aspartate in the wild-type ASPA reaction product.

[0182] Table 1 shows the aspartate content of the reaction products after 2 h incubation of 50 μl lysates from HeLa cells transfected with wild-type ASPA plasmid (WT) or nonfunctional E285 ASPA (E285A) with 5 mM NAA. Reactions were performed in 200 μl mixtures containing 50 mM Tris-HCL (pH 8.0), 50 mM NaCl, 0.5 mM DTT, 0.05% IPEGAL CA630, and 5 mM NAA. Reactions were stopped by heating to 95°C for 3 min. 20 μl of the reaction mixture was assayed for aspartate concentration by HPLC analysis of OPA-derivatized samples. Five separate samples were assayed for each transfection group. [Table 2]

[0183] Example 3 AAV-ASPA treatment of SOD G93A mice Eight-week-old male SOD G93A mice were given 1x10 11 AAV9-CBh-ASPA vector genome (vg) was transduced. Mice were anesthetized by inhalation anesthesia (isoflurane, 4% induction, maintenance dose titrated to effect) and vector was delivered in a volume of 5 μl. Control animals received 5 μl saline (0.9%) via the same route of administration (ROA). Animals were tested on an accelerating rotarod (4–40 rpm) once a week from 9–16 weeks of age. The mean fall latency over three consecutive 3-min trials was recorded (with a 30-s rest period between individual trials). Weeks 9–11 were designated as the training session, and fall latencies at weeks 12, 13, 14, 15, and 16 were compared between saline-treated and AAV9-ASPA-treated groups (n=15 / group). Rotarod analysis was performed by individuals blinded to the treatment groups. Mutant mice treated with AAV9-ASPA showed long-term improvements in rotarod performance (latency to fall) that were statistically significant at 15 and 16 weeks of age (p=0.0218 and 0.0271, respectively).

[0184] Increased NAA catabolism in AAV9-ASPA-treated SOD G93A animals is associated with an increased ATP:AMP ratio.

[0185] NAA is characteristically decreased in association with increasing pathological energy deficit in a wide range of neurodegenerative diseases, including ALS. The central hypothesis of the current study is that this metabolic response is due to an attempt to uncouple NAA synthesis from mitochondrial oxidative phosphorylation and ATP synthesis due to a common requirement for free aspartate by both synthetic processes. Thus, as per the data presented in Figure 9, liberation of aspartate from endogenous NAA by exogenously supplied ASPA would be expected to support ATP synthesis by mitochondria via a shuttle mechanism that facilitates import of cytosolic aspartate into mitochondria for use in the mitochondrial electron transport chain (ETC). The current intervention is expected to support this hypothesis with data consistent with NAA-supplied aspartate acting as a fuel for the ETC, measured as an increase in available energy currency. The primary metric in this regard is the functionality of the ASPA transgene. The functionality of AAV-delivered ASPA was confirmed in spinal cords isolated from 16-week-old SOD G93A animals immediately following rotarod analysis at 16 weeks of age. Age-matched C57BL / 6J wild-type (non-SOD) male mice were used as a calibration reference control. Spinal cords of AAV9-ASPA and saline control SOD G93A mice were analyzed by HPLC for NAA, AMP, and ATP content. Snap-frozen whole spinal cords were obtained from 16-week-old animals immediately after rotarod analysis at 16 weeks of age. Whole spinal cords were homogenized in precipitation solution using a mechanical dispersion element and extracted with chloroform. Samples thus prepared were aliquoted and stored at -80 °C for subsequent analysis. Absolute molar concentrations of target metabolites were calculated using standard curves generated from purified reference standards. In line with previously reported reductions of this metabolite in both clinical and animal model populations, 16-week-old saline-treated SOD G93A mice showed a reduction in spinal cord NAA compared to the wild-type reference (p=0.0015, n=5 / group, FIG. 11). Spinal cords from saline-treated mutant mice also showed a decreased ATP:AMP ratio (p=0.0134), suggesting that the hydrolysis (i.e., use) of ATP exceeded its synthesis.Spinal cords treated with SOD G93A AAV9-ASPA showed an additional 1.7-fold reduction in NAA compared to saline-treated controls (p=0.011, n=5 / group), associated with a significant increase in the ATP:AMP ratio (p=0.0045), suggesting functionality of the AAV-delivered ASPA transgene, increasing ATP production and improving energy status. This implies that increased products of NAA catabolism resulting from AAV9-ASPA transduction support bioavailable energy currency with associated benefits for motor function (Figure 10).

[0186] Spinal cord mitochondria treated with AAV9-ASPA exhibit increased levels of ATP synthesis that appear relative to available NAA-derived aspartate.

[0187] Intact mitochondria were isolated from the spinal cord of saline- and AAV9-ASPA-treated SOD G93A mutant mice, as well as from 16-week-old age-matched wild-type controls, and used to assess ATP synthesis rate using a luminescence-based assay. Mitochondria from each cohort were provided with ADP, and the rate of conversion to ATP was assessed over 3 min and expressed as the average ATP synthesis rate (nM / min / mg of mitochondrial protein) (Figure 12). The ATP synthesis rate of saline-treated spinal mitochondria from 16-week-old SOD G93A mice was reduced 1.7-fold compared to age-matched wild-type controls (p=0.00058), indicating a pathological energy crisis. The ATP synthesis rate of AAV9-ASPA-treated SOD G93A mitochondria was significantly increased over saline controls (p=0.0022) (Figure 10B), consistent with improved ATP:AMP ratio, indicating that it is possible to restore impaired motor function by promoting mitochondrial oxidative metabolism through ASPA catabolizing aspartate.

[0188] While the invention has been described with emphasis on embodiments, it will be apparent to those skilled in the art that variations in the compositions and methods may be used, and that it is contemplated that the invention may be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications encompassed within the spirit and scope of the invention as defined by the following claims.

Claims

1. A nucleic acid encoding aspartoacylase (ASPA) having the amino acid sequence of SEQ ID NO: 1 carried in a recombinant adeno-associated virus (rAAV) vector, 1. A therapeutically effective amount of a composition for use in treating a subject at risk of developing or suffering from ALS by increasing the amount of neuronal aspartate in the spinal cord and brain by increasing NAA catabolism in the spinal cord and brain for the benefit of mitochondrial function, comprising: The composition for use, wherein the subject is identified by screening the subject for ALS.

2. The composition for use according to claim 1, wherein administration of the composition increases NAA catabolism in brain and spinal cord tissue and enhances motor neuron survival in the subject.

3. 3. The composition for use according to claim 1 or 2, wherein the subject is administered a second therapeutic agent.

4. The composition for use according to claim 3 , wherein the second therapeutic agent is administered to the subject before, after, or simultaneously with the composition.

5. 5. The composition for use according to claim 4, wherein the second therapeutic agent is riluzole, edaravone, or a salt or solvate thereof, or a combination thereof.

6. The composition for use according to claim 1 , wherein the composition is provided as a gene therapy composition.

7. 7. The composition for use according to any one of claims 1 to 6, wherein the amino acid sequence consists of the sequence of SEQ ID NO:

1.

8. 8. The composition for use according to any one of claims 1 to 7, wherein the nucleic acid is introduced into at least one cell of the subject by viral transduction, preferably the composition is provided with a virus or virus-like particle comprising the nucleic acid.

9. The composition for use according to any one of claims 1 to 8, wherein the composition is administered to at least a portion of the brain and spinal cord of the subject.

10. 10. The composition for use according to any one of claims 1 to 9, wherein the composition is administered by a route selected from oral, parenteral, transdermal, pulmonary, intranasal, buccal, intrathecal, and intravenous, preferably the intrathecal route.

11. The composition for use according to any one of claims 1 to 10, wherein the subject is a mammal or, preferably, a human.

12. 12. The composition for use according to any one of claims 1 to 11, wherein treating a subject comprises treating at least one symptom of ALS or mitochondrial dysfunction.

13. The composition for use according to any one of claims 1 to 12, wherein the rAAV vector is a rAAV1 vector.

14. 1. A kit for use in treating a subject at risk of developing or suffering from ALS by increasing the amount of neuronal aspartate in the spinal cord and brain by increasing NAA catabolism in the spinal cord and brain for the benefit of mitochondrial function, comprising: The kit comprises an rAAV1 vector or a virus-like particle comprising an rAAV1 vector, The virus or virus-like particle comprises a nucleic acid encoding ASPA having the amino acid sequence of SEQ ID NO:1.

Citation Information

Patent Citations

  • Boost circuit

    JP2011504088A

  • CNS-targeting AAV vector and its usage method

    JP2013531471A

  • Metabolic therapy for oxidative stress in the brain through targeted neuronal catabolism of n-acetyl-aspartic acid

    US20130323229A1

  • Methods and compositions for treating metabolic imbalance

    WO2017181105A1

Cited By

  • Methods of treating or preventing amyotrophic lateral sclerosis

    JP2024133479A

  • Methods of treating or preventing amyotrophic lateral sclerosis

    US12508327B2